US20140128497A1 - Functionalized adhesive medical gel - Google Patents
Functionalized adhesive medical gel Download PDFInfo
- Publication number
- US20140128497A1 US20140128497A1 US14/154,338 US201414154338A US2014128497A1 US 20140128497 A1 US20140128497 A1 US 20140128497A1 US 201414154338 A US201414154338 A US 201414154338A US 2014128497 A1 US2014128497 A1 US 2014128497A1
- Authority
- US
- United States
- Prior art keywords
- reactive members
- specific binding
- binding pair
- medical gel
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000853 adhesive Substances 0.000 title description 6
- 230000001070 adhesive effect Effects 0.000 title description 6
- 230000000295 complement effect Effects 0.000 claims abstract description 45
- 230000009870 specific binding Effects 0.000 claims abstract description 36
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- 239000000758 substrate Substances 0.000 claims abstract description 21
- 239000002243 precursor Substances 0.000 claims abstract description 12
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000005698 Diels-Alder reaction Methods 0.000 claims abstract description 10
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 claims abstract description 6
- 238000006596 Alder-ene reaction Methods 0.000 claims abstract description 4
- 239000000499 gel Substances 0.000 claims description 91
- 239000000017 hydrogel Substances 0.000 claims description 38
- -1 polyphosphoesters Polymers 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 229920000642 polymer Polymers 0.000 claims description 18
- 150000001345 alkine derivatives Chemical class 0.000 claims description 10
- 150000001540 azides Chemical class 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 9
- 229920001400 block copolymer Polymers 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims description 8
- 150000001336 alkenes Chemical class 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 150000003573 thiols Chemical class 0.000 claims description 7
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims description 6
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 6
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical compound C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 claims description 5
- 150000001993 dienes Chemical class 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 4
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 4
- 229920001610 polycaprolactone Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 229920002732 Polyanhydride Polymers 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920000458 Polyglycolide-block-poly(ethylene glycol)-block-polyglycolide Polymers 0.000 claims description 3
- 229920001710 Polyorthoester Polymers 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 3
- 229920013820 alkyl cellulose Polymers 0.000 claims description 3
- 229920006187 aquazol Polymers 0.000 claims description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 3
- 229920000359 diblock copolymer Polymers 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 3
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 3
- 239000000622 polydioxanone Substances 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 238000010958 [3+2] cycloaddition reaction Methods 0.000 claims 2
- 229920006037 cross link polymer Polymers 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 15
- 210000001519 tissue Anatomy 0.000 description 66
- 239000004971 Cross linker Substances 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- 238000004132 cross linking Methods 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 239000003446 ligand Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000000178 monomer Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 150000003141 primary amines Chemical class 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000004067 bulking agent Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 5
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000005873 Huisgen reaction Methods 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 238000006352 cycloaddition reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229960000448 lactic acid Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- 0 *C#C[H].*C1=CN(C)N=N1.C.C[N-][N+]#N Chemical compound *C#C[H].*C1=CN(C)N=N1.C.C[N-][N+]#N 0.000 description 2
- 150000000177 1,2,3-triazoles Chemical class 0.000 description 2
- XFKSLINPMJIYFX-UHFFFAOYSA-N 1-sulfanylpyrrole-2,5-dione Chemical compound SN1C(=O)C=CC1=O XFKSLINPMJIYFX-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- IHFHKLORHNUNPO-QWRGUYRKSA-N 4-[(3s,4s)-3,4-dimethoxy-1-azacyclooct-5-yn-1-yl]-4-oxobutanoic acid Chemical compound CO[C@H]1CN(C(=O)CCC(O)=O)CCC#C[C@@H]1OC IHFHKLORHNUNPO-QWRGUYRKSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000027205 Congenital disease Diseases 0.000 description 2
- PGJBQBDNXAZHBP-UHFFFAOYSA-N Dimefox Chemical compound CN(C)P(F)(=O)N(C)C PGJBQBDNXAZHBP-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000004830 Super Glue Substances 0.000 description 2
- 208000037919 acquired disease Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940064734 aminobenzoate Drugs 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 229920006237 degradable polymer Polymers 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 238000009832 plasma treatment Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000565 sealant Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 239000003106 tissue adhesive Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- FUOJEDZPVVDXHI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-azido-2-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC=C(N=[N+]=[N-])C=C1C(=O)ON1C(=O)CCC1=O FUOJEDZPVVDXHI-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 150000008086 1,2-oxazoles Chemical class 0.000 description 1
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- CBYYPIYKJZCKGK-UHFFFAOYSA-N 2-(4-azidophenyl)-2-oxoacetaldehyde;hydrate Chemical group O.[N-]=[N+]=NC1=CC=C(C(=O)C=O)C=C1 CBYYPIYKJZCKGK-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AFNOHTDETQTADW-YLRIPHBZSA-N 2-azido-n-[(3s,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound OC[C@H]1OC(O)[C@@H](NC(=O)CN=[N+]=[N-])[C@@H](O)[C@@H]1O AFNOHTDETQTADW-YLRIPHBZSA-N 0.000 description 1
- SUHXTVABLHHRST-UHFFFAOYSA-N 2-azidoacetyl chloride Chemical compound ClC(=O)CN=[N+]=[N-] SUHXTVABLHHRST-UHFFFAOYSA-N 0.000 description 1
- NCVSUOAKBRMSMN-UHFFFAOYSA-N 3,4-dimethoxy-1-azacyclooct-5-yne Chemical group COC1CNCCC#CC1OC NCVSUOAKBRMSMN-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- SGOPTIXZYZGFBE-UHFFFAOYSA-N 3-azidopropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCN=[N+]=[N-] SGOPTIXZYZGFBE-UHFFFAOYSA-N 0.000 description 1
- XJOZVHUKILXBEV-UHFFFAOYSA-N 3-chlorooxepan-2-one Chemical compound ClC1CCCCOC1=O XJOZVHUKILXBEV-UHFFFAOYSA-N 0.000 description 1
- ZKLKEWBTKKONGD-UHFFFAOYSA-N 3-prop-2-ynyloxan-2-one Chemical compound O=C1OCCCC1CC#C ZKLKEWBTKKONGD-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- WXGJBOLTLZUJKW-XJHGOJRRSA-N C1=CCC=C1.C1=CCCC=C1.C=C1C=CC=CC1=C.C=CC#N.C=CC(=C)C.C=CC(C)=O.C=CC=C.CCCC(=O)OC.COC(=O)/C=C\C(=O)OC.COC(=O)C#CC(=O)OC.O=C1C=CC(=O)CC1.O=C1C=CC(=O)O1.O=C=O Chemical compound C1=CCC=C1.C1=CCCC=C1.C=C1C=CC=CC1=C.C=CC#N.C=CC(=C)C.C=CC(C)=O.C=CC=C.CCCC(=O)OC.COC(=O)/C=C\C(=O)OC.COC(=O)C#CC(=O)OC.O=C1C=CC(=O)CC1.O=C1C=CC(=O)O1.O=C=O WXGJBOLTLZUJKW-XJHGOJRRSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- MGJKQDOBUOMPEZ-UHFFFAOYSA-N N,N'-dimethylurea Chemical compound CNC(=O)NC MGJKQDOBUOMPEZ-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000003800 Staudinger reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005038 alkynylalkyl group Chemical group 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 238000010462 azide-alkyne Huisgen cycloaddition reaction Methods 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000003103 bodily secretion Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000005495 cold plasma Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013581 critical reagent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000005676 cyclic carbonates Chemical class 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 description 1
- FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 1
- LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 210000003236 esophagogastric junction Anatomy 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical compound OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- JMRZMIFDYMSZCB-UHFFFAOYSA-N morpholine-2,5-dione Chemical class O=C1COC(=O)CN1 JMRZMIFDYMSZCB-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 150000002843 nonmetals Chemical class 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- XNQULTQRGBXLIA-UHFFFAOYSA-O phosphonic anhydride Chemical compound O[P+](O)=O XNQULTQRGBXLIA-UHFFFAOYSA-O 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001042 poly(δ-valerolactone) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- KVFXZMLGZVYVHE-UHFFFAOYSA-N prop-2-ynyl 5-methyl-2-oxo-1,3-dioxane-5-carboxylate Chemical compound C#CCOC(=O)C1(C)COC(=O)OC1 KVFXZMLGZVYVHE-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000003894 surgical glue Substances 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940033618 tisseel Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
Definitions
- the present disclosure relates to adhesive modalities for repair of biological tissues.
- tissue glue Medical adhesives or “tissue glue” have much potential in medicine. Certain adhesive materials are known which may be used to adhere tissue such as skin. For example, cyanoacrylate adhesives been used to bond tissue. In addition to cyanoacrylate adhesives, other types of materials have been reported to adhere to skin. For example, U.S. Pat. No. 4,839,345 to Doi et al. reports a hydrated crosslinked protein adhesive gel that is used as a cataplasm or cosmetic mask that will externally adhere to skin but can be removed and then re-adhered to the skin. Other crosslinked protein hydrogels have been reported to serve as a proteinaceous substrate to deliver therapeutic agents such as enzymes or drugs through skin or mucous membranes.
- hemostatic agents have been used as hemostatic agents to stop or prevent bleeding.
- mixtures of fibrinogen and thrombin such as TISSEEL® sealant available from Baxter International, Inc. or BERIPLAST-P® hemostatic agent or sealant available from Aventis Behring, have been used in vascular surgery to seal tissue such as blood vessels and thus prevent blood leakage.
- surgical adhesives can tend to form a physical barrier between the item or items being attached to biological tissue, thus interfering with tissue ingrowth into the item when ingrowth is desired.
- hydrogels typically have excellent compatibility with human and animal tissue. Physically cross linked hydrogels can withstand attack by body fluids, blood, urine and other bodily secretions without significant damage. Many are typically non-adherent to tissue, do not have an affinity for binding to proteins and do not have cell adsorption. Hydrogels are typically non-thrombogenic. These characteristics have been utilized, e.g., for prevention of adhesions after surgery. The ability of hydrogels to act as bulking agents has been utilized in connection with treatment of gastroesophageal reflux disease (GERD), urinary incontinence, fecal incontinence and sterilization of mammals. Hydrogels have also been used to create a matrix in the treatment of damaged cartilage.
- GERD gastroesophageal reflux disease
- Click chemistry is a popular term for reliable reactions that make it possible for certain chemical building blocks to “click” together and form an irreversible linkage. See, e.g., US Pub. No. 2005/0222427.
- azide-alkyne click chemistry the reactions may be catalyzed or uncatalyzed.
- copper-free click chemistry was recently developed by Bertozzi and colleagues using difluorinated cyclooctyne or DIFO, that reacts with azides rapidly at physiological temperatures without the need for a toxic catalyst. See, e.g., Baskin et al., Copper Free Click Chemistry for Dynamic In Vivo Imaging, PNAS, vol. 104, no. 43, 16793-16797 (Oct.
- the critical reagent a substituted cyclooctyne, possesses ring strain and electron-withdrawing fluorine substituents that together promote a [3+2] dipolar cycloaddition with azides.
- a substituted cyclooctyne possesses ring strain and electron-withdrawing fluorine substituents that together promote a [3+2] dipolar cycloaddition with azides.
- Another suitable cyclooctyne is 6,7-dimethoxyazacyclooct-4-yne (DIMAC).
- a method for adhering a medical gel to biological tissue includes providing a medical gel having a plurality of reactive members of a specific binding pair attached on to a medical gel or to precursor molecules of the medical gel, and providing tissue with a plurality of complementary reactive members of the specific binding pair, wherein upon contact of the reactive members of the medical gel with the complimentary reactive members on the tissue, covalent bonds are formed between the reactive members and the complementary reactive members, thus adhering the medical gel to the tissue.
- a bioadherent substrate which includes a medical gel having a plurality of reactive members of a specific binding pair attached thereto, said reactive members being capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair via a reaction selected from a Huisgen cycloaddition, a Diels-Alder reaction, a thiol-alkene reaction.
- a kit which includes a functionalized medical gel or medical gel precursor molecules having a plurality of reactive members of a specific binding pair adapted to be attached to the gel or medical gel precursor molecules; a container containing a solution or suspension of complementary reactive members of the specific binding pair, the complementary reactive members having a functionality that will adhere them to biological tissue upon contact; and at least one applicator adapted to deliver the functionalized medical gel or medical gel precursors or the solution or suspension to biological tissue.
- a surgical adhesive system for medical gels and biological tissue which covalently bonds reactive members of a specific binding pair to one another via click chemistry.
- Click chemistry refers to a collection of reactive members having a high chemical potential energy capable of producing highly selective, high yield reactions. The reactive members react to form extremely reliable molecular connections in most solvents, including physiologic fluids, and often do not interfere with other reagents and reactions. Examples of click chemistry reactions include Huisgen cycloaddition, Diels-Alder reactions, thiol-alkene reactions, and maleimide-thiol reactions.
- Huisgen cycloaddition is the reaction of a dipolarophile with a 1,3-dipolar compound that leads to 5-membered (hetero)cycles.
- dipolarophiles are alkenes and alkynes and molecules that possess related heteroatom functional groups (such as carbonyls and nitriles).
- 1,3-Dipolar compounds contain one or more heteroatoms and can be described as having at least one mesomeric structure that represents a charged dipole. They include nitril oxides, azides, and diazoalkanes.
- Metal catalyzed click chemistry is an extremely efficient variant of the Huisgen 1,3-dipolar cycloaddition reaction between alkyl-aryly-sulfonyl azides, C—N triple bonds and C—C triple bonds which is well-suited herein.
- the results of these reactions are 1,2 oxazoles, 1,2,3 triazoles or tetrazoles.
- 1,2,3 triazoles are formed by a copper catalyzed Huisgen reaction between alkynes and alkyl/aryl azides.
- Metal catalyzed Huisgen reactions proceed at ambient temperature, are not sensitive to solvents, i.e., nonpolar, polar, semipolar, and are highly tolerant of functional groups.
- Non-metal Huisgen reactions also referred to as strain promoted cycloaddition
- a substituted cyclooctyne which possesses ring strain and electron-withdrawing substituents such as fluorine, that together promote a [3+2] dipolar cycloaddition with azides
- Examples include DIFO and DIMAC. Reaction of the alkynes and azides is very specific and essentially inert against the chemical environment of biological tissues.
- One reaction scheme may be represented as:
- R is a polymeric backbone and R′ is a component of a biologic tissue.
- R is a component of a biologic tissue and R′ is a polymeric backbone.
- the Diels-Alder reaction combines a diene (a molecule with two alternating double bonds) and a dienophile (an alkene) to make rings and bicyclic compounds.
- diene a molecule with two alternating double bonds
- dienophile an alkene
- the thiol-alkene (thiol-ene) reaction is a hydrothiolation, i.e., addition of RS—H across a C ⁇ C bond.
- the thiol-ene reaction proceeds via a free-radical chain mechanism. Initiation occurs by radical formation upon UV excitation of a photoinitiator or the thiol itself.
- Thiol-ene systems form ground state charge transfer complexes and therefore photopolymerize even in the absence of initiators in reasonable polymerization times.
- the addition of UV light increases the speed at which the reaction proceeds.
- the wavelength of the light can be modulated as needed, depending upon the size and nature of the constituents attached to the thiol or alkene.
- a general thiol-ene coupling reaction mechanism is represented below:
- a medical gel such as a hydrogel
- a medical gel is provided with a plurality of reactive members of a specific binding pair attached on the surface of the gel or to precursor molecules which form the gel.
- “attached to the surface of the gel” or “attached on the surface of the gel” or “located on the gel” is intended to include attachment to molecules which are precursors of the gel.
- the reactive members of the medical gel are contacted with biological tissue containing complementary reactive members of the specific binding pair, covalent attachment occurs, thus adhering the gel to the tissue.
- the reactive members may be either a dipolarophile or a 1,3 dipolar compound depending on which complement is applied to the target tissue or the medical gel.
- the Diels-Alder members of a specific binding pair may be either a diene and a dienophile depending on which complement is applied to the target tissue or the medical gel. For example, if a diene is located on the gel, the dienophile can be located on the tissue. If a diene is located on the tissue, the dienophile can be located on the gel.
- the thiol-ene members of a specific binding pair may be either a thiol and an alkene depending on which complement is applied to the target tissue or the gel. For example, if a thiol is located on the gel, the alkene can be located on the tissue. If a thiol is located on the tissue, the alkene can be located on the gel.
- the medical gel may be biocompatible and absorbable or biocompatible and non-absorbable.
- the reactive members are attached directly to the polymeric backbone of the gel.
- the reactive members are attached to the polymeric backbone via a cross-linker.
- Cross-linkers are discussed below.
- Hydrogels can be formed, e.g., when an organic polymer, also referred to herein as precursor molecules which form the gel, which can be natural or synthetic, is set or at least partially solidified to create a three-dimensional open-lattice structure that entraps molecules of water or other solutions to form a gel. Hydrogels have an affinity for water and typically swell in water, but do not necessarily dissolve in water.
- hydrogels are formed by polymerization and crosslinking of a hydrophilic monomer in an aqueous solution to cause the solution to gel.
- the hydrogel is composed of 85% water, to which can be added any salt or adjuvant.
- Hydrogels may be organic gels or inorganic gels.
- Organic gels from which the hydrogel of the invention can be selected include, by way of example and not by way of limitation, gels formed from polysaccharides and mucopolysaccharides including, but not limited to hyaluronic acid, dextran, heparin sulfate, chondroitin sulfate, agar, starch, and alginate; proteins, including but not limited to, fibronectin, gelatin, collagen, fibrin, chitosan, chitin, pectins, albumin, ovalbumin, and polyamino acids; collagen-hydroxyethyl-methacrylate (HEMA); polyphosphazines; polyphosphoesters; polyethylene glycol; polyethylene oxide; polyvinyl alcohol; polyvinylpyrrolidone; polyethyloxazoline; polyethylene oxide-co-polypropyleneoxide block copolymers; PGA-PEG-PGA block copo
- Collagen-hydroxyethyl-methacrylate (EMA) hydrogel polymer is commonly formed from a gelled and crosslinked hydrophilic monomer solution to form a three dimensional polymeric meshwork anchoring macromolecules.
- Crosslinking of the hydrophilic monomer solution can be accomplished by free radical polymerization of hydrophilic monomers, such as hydroxyethyl-methacrylate (HEMA).
- Hydrogel polymers formed by free radical polymerization of monomer solutions require crosslinking to form the three dimensional network to gel the aqueous solution.
- HEMA monomer solutions typically can be crosslinked to gel by dimethacrylate, although other crosslinking agents, such as ethylene glycol dimethacrylate or methylmethacrylate, can also be used during polymerization to modify the hydrogel.
- a wide variety of other hydrophilic monomers may also be suitable for purposes of the invention.
- Inorganic gels include, by way of example and not by way of limitation, silica, alumina, and ferric oxide.
- Bulk and cellular hydrogels may be prepared by covalent cross linking or physical cross linking of the hydrogel molecules.
- covalent cross linking also known as chemical cross linking
- chemical cross linking includes the use of multi-functional reactive chemical molecules such as aldehydes, maleic acid, dimethyl urea, di-isocyanates, boric acid, and the like, and also the use of ionizing radiation, ultraviolet light, and the like
- physical cross linking methods also known as reversible cross linking, includes cross linking through crystallites, hydrogen bonding and complexing agents such as titanium, aluminum, manganese, and copper, to name a few.
- bioresorbable and “bioabsorbable” are used interchangeably and are intended to mean the characteristic according to which an implant and/or a material is resorbed by the biological tissues and the surrounding fluids and disappears in vivo after a given period of time, that may vary, for example, from one day to several months, depending on the chemical nature of the implant and/or of the material.
- Non bioresorbable material also called permanent material—is not substantially resorbed by tissues and surrounding fluids, after 2 years and more, keeping in particular most (e.g., >80%) of their mechanical properties after such a time.
- biocompatible is intended to mean the characteristic according to which an implant and/or a material is well integrated by the biological tissues and the surrounding fluids without inducing excessive inflammation reaction around the bulk of the material or due to its degradation.
- the material should avoid also the formation of a fibrous capsule which usually results in the delay of the cellular integration of a porous implant.
- the reactive members are attached to the medical gel by surface modification techniques such as plasma treatment, silane coupling treatment and acid sensitization.
- Surface activation of the medical gel can be achieved by acid or base hydrolysis, treatment by means of cold plasma, by chemical reactions or electromagnetic radiations.
- Hydrolysis can be conducted in the presence of an aqueous solution of a base or an acid to accelerate surface reaction, inasmuch as excessively long processes of activation can induce a reduction in molecular weight and thus in the mechanical properties of the material.
- Suitable bases for obtaining watery solutions suited to the aim are, for example, strong alkalis, such as LiOH, Ba(OH) 2 , Mg(OH) 2 , NaOH, KOH, Na 2 CO 3 , Ca(OH) 2 and the weak bases, such as for example NH 4 OH and the amines such as methylamine, ethylamine, diethylamine and dimethylamine.
- Acids suitable for surface hydrolysis treatments can be chosen, for example, from among HCl, HClO 3 , HClO 4 , H 2 SO 3 , H 2 SO 4 , H 3 PO 3 , H 3 PO 4 , HI, HIO 3 , HBr, lactic acid, glycolic acid.
- Surface activation by means of hydrolysis can be conducted at temperatures preferably comprised between 0 degrees Celsius and the material softening temperature.
- Plasma treatment can be carried out both in the presence of a reactive gas, for example air, Ar, O 2 with the formation of surface activation of oxygenate type, such as —OH, —CHO, —COOH.
- a reactive gas for example air, Ar, O 2
- oxygenate type such as —OH, —CHO, —COOH.
- the COONa groups generated by a base hydrolysis can be subsequently converted into COOH groups by treatment with strong mineral acids.
- the surface freeing of alcoholic groups by means of a hydrolysis process can be followed by reaction by means of the addition of a compound provided with functional group or groups able to react with surface alcoholic groups, such as for example by means of the addition of an anhydride such as succinic anhydride, with the conversion of —OH groups into —O—CO—CH 2 —CH 2 —COOH groups.
- Suitable surface activation techniques are disclosed in U.S. Pat. No. 6,107,453, the entire disclosure of which is incorporated herein by this reference.
- pendant functional groups can be incorporated into the polymer backbone by, e.g., copolymerization with functionalized monomer such as lactones, cyclic carbonates and morpholine-2,5-diones.
- the azido group, N 3 is a nucleophilic group that will exchange with other nucleophilic groups, e.g., —OH, —NH 2 and halogens (Br, Cl, or I).
- 1,3-dipolar compounds may be conjugated to aliphatic polyesters, by copolymerizing, e.g., ⁇ -caprolactone and ⁇ -chloro- ⁇ -caprolactone and then substituting an azide group for the Cl atom.
- Polyesters can incorporate pendant dipolarophiles, e.g., propargyl groups, by copolymerization of ⁇ -caprolactone and ⁇ -propargyl- ⁇ -valerolactone.
- Copolymers of L-lactide containing propargyl groups may, e.g., be prepared by ring opening copolymerization of 5-methyl-5-propargyloxycarbonyl-1,3-dioxanone with L-lactide at a molar ratio of about 90:10 with ZnEt 2 as a catalyst. See, Shi et al., Biomaterials, 29 (2008)1118-1126.
- Azide functionalized polystyrene is synthesized using atom transfer radical polymerization and subsequent modification with azidotrimethylsilane and tetrabutylammonium fluoride. See, Dirks, et al., Chem. Comm., (2005) 4172-4174. Azides may be incorporated onto methacrylates, e.g., 3 azidopropyl methacrylate which is copolymerized to a block copolymer. Diels-Alder functionalities and thiol-ene functionalities are likewise incorporated into polymers herein.
- Biological tissue is provided with reactive members or complementary reactive members of a specific binding pair by conjugation to various components of tissue such as proteins, lipids, oligosaccharides, oligonucleotides, glycans, including glycosaminoglycans.
- the reactive members or complementary reactive members are attached directly to components of the tissue.
- the reactive members or complementary reactive members are attached to components of the tissue via a linker.
- situating the reactive members or complementary reactive members on the tissue can be accomplished by suspending the reactive members or complementary reactive members in a solution or suspension and applying the solution or suspension to the tissue such that the reactive member or complementary reactive members binds to a target.
- the solution or suspension may be poured, sprayed or painted onto the tissue, whereupon the reactive members are incorporated into the tissue.
- 1,3-Dipolar compounds can be incorporated into proteins, lipids, oligosaccharides, oligonucleotides and glycans using, e.g., metabolic machinery, covalent inhibitors and enzymatic transfers.
- an azido group, N 3 can be applied at the N-terminus of proteins or peptides using azidoacetyl chloride. See, e.g., Haridas, et al., Tetrahedron Letters 48 (2007) 4719-4722.
- the azido group is a nucleophilic group that will exchange with other nucleophilic groups, e.g., —OH, —NH 2 and halogens (Br, Cl, or I).
- NaN 3 is an azidizing agent which is capable of aziding proteins by simply contacting the proteins with a 10 times molar excess of NaN 3 .
- a process for C-terminal azidization is described in Cazalis, et al., Bioconjugate Chem., 15 (2004) 1005-1009. Incubation of cells with peracetylated N-azidoacetylmannosamine provides cell surface glycans with azido sialic acid. See, e.g., Codelli et al., J. Amer. Chem. Soc., 130 (34) 11486-11493 (2008).
- PEGylation is a commonly used technique for adding groups to peptides and proteins and is suitable for use herein.
- PEG may be covalently bound to amino acid residues via a reactive group.
- Reactive groups are those to which an activated PEG molecule may be bound (e.g., a free amino or carboxyl group).
- N-terminal amino acid residues and lysine (K) residues have a free amino group and C-terminal amino acid residues have a free carboxyl group.
- Sulfhydryl groups may also be used as a reactive group for attaching PEG.
- enzyme-assisted methods for introducing activated groups e.g., hydrazide, aldehyde, and aromatic-amino groups
- PEG incorporating 1,3-dipolar compounds may be utilized herein Those skilled in the art can utilize any known process for coupling a 1,3-dipolar compound into proteins, lipids, oligosaccharides, oligonucleotides and glycans.
- Dipolarophile functionalized proteins and peptides can be synthesized by linking at the N-terminus with, for example, an alkyne (e.g., 3 butynyl chloroformate), in connection with a tripeptide (GlyGlyArg).
- alkyne e.g., 3 butynyl chloroformate
- GlyGlyArg a tripeptide herein is the well-known cell adhesion sequence RGD.
- proteins is intended to encompass peptides and polypeptides.
- thiols on cysteines are functionalized with alkyne bearing maleimide. Id.
- Providing a C-terminal dipolarophile can be accomplished, e.g., by coupling with propargylamine using a cross-linking agent such as N-hydroxysuccinimide/DCC.
- Terminal alkynes can be installed using metabolic building blocks such as alkynoic acids. Lipids may be functionalized with alkynes.
- alkyne modified fatty acids can be generated by reaction of terminal alkynyl-alkyl bromide with trimethyl phosphine to yield a 16-carbon alkynyl-dimethylphosphonate. See, e.g., Raghavan et al., Bioorg. Med. Chem.
- PEGylation may be used for adding dipolarophile groups to peptides and proteins and is suitable for use herein.
- Diels-Alder functionalities and thiol-ene functionalities are likewise attached to proteins, lipids, oligosaccharides, oligonucleotides and glycans.
- the reactive members or complementary reactive members may be also attached to biological tissue or the medical gel via a linker.
- the linker is or includes a ligand which bears a reactive member.
- the ligand binds to a desired target on the tissue and thus provides a vehicle for transporting and indirectly binding the reactive member or complementary reactive member to the tissue.
- the ligand herein is any molecule or combination of molecules which demonstrates an affinity for a target. Examples of ligands include nucleic acid probes, antibodies, hapten conjugates, and cell adhesion peptides such as RGD. The mechanisms involved in obtaining and using such ligands are well-known.
- reactive members or complementary reactive members are incorporated into saccharides or polysaccharides and metabolically incorporated into cells. See, e.g., Baskin et al., supra.
- Antibodies that specifically recognize antigens are useful in accordance with one embodiment herein.
- Antibodies which are conjugated to a reactive member or complementary reactive members are utilized to bind to proteins located on tissue.
- Monoclonal or polyclonal antibodies are raised against an antigen which can be any component of biological tissue and then purified using conventional techniques.
- the term “antibody” is intended to include whole antibodies, e.g., of any isotype (IgG, IgA, IgM, IgE, etc.), and to include fragments thereof which are also specifically reactive with a vertebrate, e.g., mammalian, protein.
- Antibodies may be fragmented using conventional techniques and the fragments screened for utility in the same manner as for whole antibodies.
- the term includes segments of proteolytically-cleaved or recombinantly-prepared portions of an antibody molecule that are capable of selectively reacting with a certain protein.
- proteolytic and/or recombinant fragments include Fab, F(ab′)2, Fab′, Fv, and single chain antibodies (scFv) containing a V[L] and/or V[H] domain joined by a peptide linker.
- the scFv's may be covalently or non-covalently linked to form antibodies having two or more binding sites.
- the present disclosure includes polyclonal, monoclonal or other purified preparations of antibodies and recombinant antibodies.
- the ligands e.g., antibodies, nucleic acid probes, hapten conjugates and cell adhesion peptides
- reactive members or complementary reactive members can be linked to ligands by cross-linking procedures which, in accordance with the present invention, do not cause denaturing or misfolding of the ligands.
- the terms “linked” or “conjugated” as used herein are used interchangeably and are intended to include any or all of the mechanisms known in the art for coupling the reactive members or complementary reactive members to the ligand.
- any chemical or enzymatic linkage known to those with skill in the art is contemplated including those which result from photoactivation and the like.
- Homofunctional and heterobifunctional cross linkers are all suitable.
- Reactive groups (distinguishable from reactive members or complementary reactive members herein) which can be cross-linked with a cross-linker include primary amines, sulfhydryls, carbonyls, carbohydrates and carboxylic acids.
- Cross-linkers are conventionally available with varying lengths of spacer arms or bridges.
- Cross-linkers suitable for reacting with primary amines include homobifunctional cross-linkers such as imidoesters and N-hydroxysuccinimidyl (NHS) esters.
- imidoester cross-linkers include dimethyladipimidate, dimethylpimelimidate, and dimethylsuberimidate.
- NHS-ester cross-linkers include disuccinimidyl glutamate, disucciniminidyl suberate and bis(sulfosuccinimidyl) suberate.
- Accessible amine groups present on the N-termini of peptides react with NHS-esters to form amides.
- NHS-ester cross-linking reactions can be conducted in phosphate, bicarbonate/carbonate, HEPES and borate buffers. Other buffers can be used if they do not contain primary amines.
- the reaction of NHS-esters with primary amines should be conducted at a pH of between about 7 and about 9 and a temperature between about 4° C. and 30° C. for about 30 minutes to about 2 hours.
- the concentration of NHS-ester cross-linker can vary from about 0.1 to about 10 mM.
- NHS-esters are either hydrophilic or hydrophobic. Hydrophilic NHS-esters are reacted in aqueous solutions although DMSO may be included to achieve greater solubility. Hydrophobic NHS-esters are dissolved in a water miscible organic solvent and then added to the aqueous reaction mixture.
- Sulfhydryl reactive cross-linkers include maleimides, alkyl halides, aryl halides and a-haloacyls which react with sulfhydryls to form thiol ether bonds and pyridyl disulfides which react with sulfhydryls to produce mixed disulfides.
- Sulfhydryl groups on peptides and proteins can be generated by techniques known to those with skill in the art, e.g., by reduction of disulfide bonds or addition by reaction with primary amines using 2-iminothiolane.
- maleimide cross-linkers include succinimidyl 4- ⁇ N-maleimido-methyl)cyclohexane-1-carboxylate and m-maleimidobenzoyl-N-hydroxysuccinimide ester.
- haloacetal cross-linkers include N-succinimidyl(4-iodoacetal)aminobenzoate and sulfosuccinimidyl(4-iodoacetal)aminobenzoate.
- pyridyl disulfide cross-linkers examples include 1,4-Di-[3′-2′-pyridyldithio(propionamido)butane] and N-succinimidyl-3-(2-pyridyldithio)-propionate.
- Carboxyl groups are cross-linked to primary amines or hydrazides by using carbodimides which result in formation of amide or hydrazone bonds. In this manner, carboxy-termini of peptides or proteins can be linked.
- carbodiimide cross-linkers include 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride and N, N 1 -dicyclohexylcarbodiimide.
- Arylazide cross-linkers become reactive when exposed to ultraviolet radiation and form aryl nitrene.
- arylazide cross-linkers examples include azidobenzoyl hydrazide and N-5-azido-2 nitrobenzoyloxysuccinimide.
- Glyoxal cross linkers target the guanidyl portion of arginine.
- An example of a glyoxal cross-linker is p-azidophenyl glyoxal monohydrate.
- Heterobifunctional cross-linkers which possess two or more different reactive groups are suitable for use herein.
- Examples include cross-linkers which are amine-reactive at one end and sulfhydryl-reactive at the other end such as 4-succinimidyl-oxycarbonyl-a-(2-pyridyldithio)-toluene, N-succinimidyl-3-(2-pyridyldithio)-propionate and the maleimide cross-linkers discussed above.
- Attachment of reactive members or complementary reactive members to the medical gel functionalizes the gel such that upon exposure to their complementary reactive members which are situated on tissue, they are activated and form a covalent bond, thus adhering the gel to the tissue.
- a linker between the product of the reactive members or complementary reactive members and the biological tissue is degradable by, e.g., hydrolysis or enzymatic action. In this manner, the medical gel can be removable after a period of time.
- the degradable linkage may be chelates or chemically or enzymatically hydrolyzable or absorbable.
- Illustrative chemically hydrolyzable degradable linkages include polymers, copolymers and oligomers of glycolide, dl-lactide, 1-lactide, caprolactone, dioxanone, and tritnethylene carbonate.
- Illustrative enzymatically hydrolyzable biodegradable linkages include peptidic linkages cleavable by metalloproteinases and collagenases and chitosan cleavable by lysozyme.
- degradable linkages include polymers and copolymers of poly(hydroxy acid)s, poly(orthocarbonate)s, poly(anhydride)s, poly(lactone)s, poly(amino acid)s, poly(carbonate)s, poly(saccharide)s and poly(phosphonate)s.
- the degradable linkage may contain ester linkages.
- Some non-limiting examples include esters of succinic acid, glutaric acid, propionic acid, adipic acid, or amino acids, as well as carboxymethyl esters.
- the ligand solution and gel can be sterilized by any known method, e.g., irradiation, ethylene oxide, filtration in sterile conditions on a 0.22 um filter and the like.
- the gel is an uncured liquid, functionalized with a plurality of reactive members of a binding pair, which is applied and cured as a layer on surfaces of internal organs or tissues which were pretreated with the complementary reactive member as described above.
- the target tissue is pretreated by spraying, painting or pouring a solution or suspension containing the complementary reactive members of a binding pair on to the tissue.
- Ligands associated with the reactive members or complementary reactive members bind to their predetermined targets on the tissue, thereby anchoring the reactive members or complementary reactive members on the tissue.
- the uncured functionalized liquid gel is sprayed over, e.g., a defect on the tissue where it cures while simultaneously, the reactive members and complementary reactive members of the specific binding pair react specifically together to form covalent bonds, providing adhesion between the tissue and the curing or cured gel.
- the functionalized gel is cured prior to application to pretreated tissue and then draped over or otherwise contacted with the target or defect to allow the covalent bond forming reaction to occur with consequent covalent bonding and adherence.
- two opposing tissue surfaces are pretreated and functionalized, and functionalized gel added to form bonds to both opposing surfaces.
- the medical gel composition may be used to bind tissue together either as an adjunct to or as a replacement of sutures, staples, tapes and/or bandages.
- the present gels may be used to prevent post-surgical adhesions.
- the gel, functionalized with a reactive member of a binding pair is applied and cured as a layer on surfaces of internal organs or tissues which were pretreated with a complementary reactive member of the binding pair as described above in order to prevent the formation of adhesions at a surgical site as the site heals.
- the functionalized gel may be used to attach pretreated skin grafts and to position pretreated tissue flaps or free flaps during reconstructive surgery.
- the functionalized gel may be used to close pretreated gingival flaps in periodontal surgery. Additional applications include sealing tissues to prevent or control blood or other fluid leaks at suture or staple lines as well as to prevent or control air leaks in the pulmonary system.
- functionalized medical gels herein can be used as bulking agents, e.g., they can be injected via a syringe and needle or other generally accepted means directly into a specific area wherever a bulking agent is desired, i.e., a pretreated soft tissue deformity such as that seen with areas of muscle atrophy due to congenital or acquired diseases or secondary to trauma, burns, and the like.
- a medical gel herein in the upper torso of a patient with muscular atrophy secondary to nerve damage.
- a medical gel herein can also be injected as a bulking agent for hard tissue defects, such as bone or cartilage defects, either congenital or acquired disease states, or secondary to trauma, burns, or the like.
- An example of this would be an injection into the area surrounding the skull where a bony deformity exists secondary to trauma. The injection in these instances can be made directly into the needed area with the use of a needle and syringe under local or general anesthesia.
- a medical gel could also be injected percutaneously by direct palpation, such as by placing a needle inside a pretreated vas deferens and occluding the same with the injected functionalized bulking medical gel, thus rendering the patient infertile.
- the gel could also be injected through a catheter or needle with fluoroscopic, sonographic, computed tomography, magnetic resonance imaging or other type of radiologic guidance. This would allow for placement or injection of the pretreatment formulation and subsequent functionalized medical gel either by vascular access or percutaneous access to specific organs or other tissue regions in the body, wherever a bulking agent would be required.
- tissue engineering employing functionalized medical gel scaffolds can be used to create alternatives to prosthetic materials currently used in craniomaxillofacial surgery, as well as formation of organ equivalents to replaced diseased, defective, or injured tissues.
- Medical gels herein can be malleable and used to encapsulate cells.
- a functionalized polymer solution is mixed with the cells to be implanted to form a suspension.
- the target site is pretreated with complementary members of a specific binding pair and the functionalized polymers in suspension are injected directly into a patient prior to crosslinking of the polymer to form the hydrogel containing the cells.
- the hydrogel cures over a short period of time while simultaneously binding to the pretreated area through covalent bond formation.
- the functionalized gel is injected or poured into a mold, where it crosslinks to form a semi-solid hydrogel of the desired anatomical shape having cells dispersed therein which then may be implanted in a pretreated target area in a patient.
- the hydrogel may be produced, for example, by cross-linking a polysaccharide polymer by exposure to a monovalent cation.
- Other polymers capable of forming functionalized hydrogels as described above may be used as disclosed herein.
- the strength of the crosslink may be increased or reduced by adjusting the concentration of the polymer and/or crosslinking agent.
- combinations in accordance with this disclosure e.g., functionalized medical gel having reactive members of a specific binding pair and functionalized pretreatment formulation containing complementary members of the specific binding pair, could be injected through a laparoscope or thoracoscope to any intraperitoneal or extraperitoneal or thoracic organ.
- the functionalized pretreatment formulation and functionalized gel could be injected in the region of the gastroesophageal junction for the correcting of gastroesophageal reflux.
- a kit for a functionalized adhesive herein includes a medical gel which has a plurality of reactive members of a specific binding pair adapted to be attached to a surface of the gel and an applicator adapted to contain a solution or suspension of complementary reactive members of the specific binding pair, the complementary reactive members having a functionality that will adhere them to biological tissue upon contact.
- the kit may optionally include a container which contains a catalyst for causing the reactive members of a specific binding pair to bind with the complementary reactive members of the specific binding pair.
- the catalyst may be a solution of metal such as copper.
- the kit contains a microwave or ultraviolet radiation generator.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Dispersion Chemistry (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
Abstract
A bioadherent substrate includes a medical gel or medical gel precursor having a plurality of reactive members of a specific binding pair attached on or adapted to be attached to a surface of the medical gel, said reactive members being capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair via a reaction selected from a Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction. A method for adhering a medical gel to biological tissue includes providing a medical gel or a medical gel precursor having a plurality of reactive members of a specific binding pair attached on or adapted to be attached to a surface of the medical gel and providing tissue with a plurality of complementary reactive members of the specific binding pair, wherein upon contact of the reactive members on the medical gel with the complimentary reactive members on the tissue, covalent bonds are formed between the reactive members and the complementary reactive members, thus adhering the medical gel to the tissue.
Description
- This application is a Divisional application of U.S. application Ser. No. 12/708,828 filed Feb. 19, 2010 which claims the benefit of U.S. Provisional Patent Application No. 61/154,369 filed Feb. 21, 2009, the entire contents of which are incorporated herein by reference.
- 1. Technical Field
- The present disclosure relates to adhesive modalities for repair of biological tissues.
- 2. Related Art
- Medical adhesives or “tissue glue” have much potential in medicine. Certain adhesive materials are known which may be used to adhere tissue such as skin. For example, cyanoacrylate adhesives been used to bond tissue. In addition to cyanoacrylate adhesives, other types of materials have been reported to adhere to skin. For example, U.S. Pat. No. 4,839,345 to Doi et al. reports a hydrated crosslinked protein adhesive gel that is used as a cataplasm or cosmetic mask that will externally adhere to skin but can be removed and then re-adhered to the skin. Other crosslinked protein hydrogels have been reported to serve as a proteinaceous substrate to deliver therapeutic agents such as enzymes or drugs through skin or mucous membranes. Still other materials have been used as hemostatic agents to stop or prevent bleeding. For example, mixtures of fibrinogen and thrombin such as TISSEEL® sealant available from Baxter International, Inc. or BERIPLAST-P® hemostatic agent or sealant available from Aventis Behring, have been used in vascular surgery to seal tissue such as blood vessels and thus prevent blood leakage. However, surgical adhesives can tend to form a physical barrier between the item or items being attached to biological tissue, thus interfering with tissue ingrowth into the item when ingrowth is desired.
- The use of medical gels such as hydrogels can be advantageous due to the physico-chemical properties of the hydrogels. Hydrogels typically have excellent compatibility with human and animal tissue. Physically cross linked hydrogels can withstand attack by body fluids, blood, urine and other bodily secretions without significant damage. Many are typically non-adherent to tissue, do not have an affinity for binding to proteins and do not have cell adsorption. Hydrogels are typically non-thrombogenic. These characteristics have been utilized, e.g., for prevention of adhesions after surgery. The ability of hydrogels to act as bulking agents has been utilized in connection with treatment of gastroesophageal reflux disease (GERD), urinary incontinence, fecal incontinence and sterilization of mammals. Hydrogels have also been used to create a matrix in the treatment of damaged cartilage.
- Click chemistry is a popular term for reliable reactions that make it possible for certain chemical building blocks to “click” together and form an irreversible linkage. See, e.g., US Pub. No. 2005/0222427. In the case of azide-alkyne click chemistry, the reactions may be catalyzed or uncatalyzed. For example, copper-free click chemistry was recently developed by Bertozzi and colleagues using difluorinated cyclooctyne or DIFO, that reacts with azides rapidly at physiological temperatures without the need for a toxic catalyst. See, e.g., Baskin et al., Copper Free Click Chemistry for Dynamic In Vivo Imaging, PNAS, vol. 104, no. 43, 16793-16797 (Oct. 23, 2007). The critical reagent, a substituted cyclooctyne, possesses ring strain and electron-withdrawing fluorine substituents that together promote a [3+2] dipolar cycloaddition with azides. See also, US Pub. No. 2006/0110782 and Codelli et al., Second Generation Difluorinated Cyclooctynes for Copper-Free Click Chemistry, J. Am. Chem. Soc., vol. 130, no. 34, 11486-11493 (2008). Another suitable cyclooctyne is 6,7-dimethoxyazacyclooct-4-yne (DIMAC). See, Sletton and Bertozzi, A hydrophilic azacyclooctyne for Cu-free click chemistry, Org. Lett. (2008) 10 (14), 3097-3099. Other click chemistry reactions include Diels-Alder reactions, thiol-alkene reactions, and maleimide-thiol reactions.
- It would be advantageous to be able to secure medical gels via selective attachment at target sites within the body to prevent migration of the hydrogel without interfering with other hydrogel properties such as durability and the ability to be generally non-adherent when or where desired.
- A method for adhering a medical gel to biological tissue is provided which includes providing a medical gel having a plurality of reactive members of a specific binding pair attached on to a medical gel or to precursor molecules of the medical gel, and providing tissue with a plurality of complementary reactive members of the specific binding pair, wherein upon contact of the reactive members of the medical gel with the complimentary reactive members on the tissue, covalent bonds are formed between the reactive members and the complementary reactive members, thus adhering the medical gel to the tissue.
- A bioadherent substrate is provided which includes a medical gel having a plurality of reactive members of a specific binding pair attached thereto, said reactive members being capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair via a reaction selected from a Huisgen cycloaddition, a Diels-Alder reaction, a thiol-alkene reaction.
- A kit is provided which includes a functionalized medical gel or medical gel precursor molecules having a plurality of reactive members of a specific binding pair adapted to be attached to the gel or medical gel precursor molecules; a container containing a solution or suspension of complementary reactive members of the specific binding pair, the complementary reactive members having a functionality that will adhere them to biological tissue upon contact; and at least one applicator adapted to deliver the functionalized medical gel or medical gel precursors or the solution or suspension to biological tissue.
- A surgical adhesive system for medical gels and biological tissue is provided which covalently bonds reactive members of a specific binding pair to one another via click chemistry. Click chemistry refers to a collection of reactive members having a high chemical potential energy capable of producing highly selective, high yield reactions. The reactive members react to form extremely reliable molecular connections in most solvents, including physiologic fluids, and often do not interfere with other reagents and reactions. Examples of click chemistry reactions include Huisgen cycloaddition, Diels-Alder reactions, thiol-alkene reactions, and maleimide-thiol reactions.
- Huisgen cycloaddition is the reaction of a dipolarophile with a 1,3-dipolar compound that leads to 5-membered (hetero)cycles. Examples of dipolarophiles are alkenes and alkynes and molecules that possess related heteroatom functional groups (such as carbonyls and nitriles). 1,3-Dipolar compounds contain one or more heteroatoms and can be described as having at least one mesomeric structure that represents a charged dipole. They include nitril oxides, azides, and diazoalkanes. Metal catalyzed click chemistry is an extremely efficient variant of the Huisgen 1,3-dipolar cycloaddition reaction between alkyl-aryly-sulfonyl azides, C—N triple bonds and C—C triple bonds which is well-suited herein. The results of these reactions are 1,2 oxazoles, 1,2,3 triazoles or tetrazoles. For example, 1,2,3 triazoles are formed by a copper catalyzed Huisgen reaction between alkynes and alkyl/aryl azides. Metal catalyzed Huisgen reactions proceed at ambient temperature, are not sensitive to solvents, i.e., nonpolar, polar, semipolar, and are highly tolerant of functional groups. Non-metal Huisgen reactions (also referred to as strain promoted cycloaddition) involving use of a substituted cyclooctyne, which possesses ring strain and electron-withdrawing substituents such as fluorine, that together promote a [3+2] dipolar cycloaddition with azides are especially well-suited for use herein due to low toxicity as compared to the metal catalyzed reactions. Examples include DIFO and DIMAC. Reaction of the alkynes and azides is very specific and essentially inert against the chemical environment of biological tissues. One reaction scheme may be represented as:
- where R is a polymeric backbone and R′ is a component of a biologic tissue. Alternatively, R is a component of a biologic tissue and R′ is a polymeric backbone.
- The Diels-Alder reaction combines a diene (a molecule with two alternating double bonds) and a dienophile (an alkene) to make rings and bicyclic compounds. Examples include:
- The thiol-alkene (thiol-ene) reaction is a hydrothiolation, i.e., addition of RS—H across a C═C bond. The thiol-ene reaction proceeds via a free-radical chain mechanism. Initiation occurs by radical formation upon UV excitation of a photoinitiator or the thiol itself. Thiol-ene systems form ground state charge transfer complexes and therefore photopolymerize even in the absence of initiators in reasonable polymerization times. However, the addition of UV light increases the speed at which the reaction proceeds. The wavelength of the light can be modulated as needed, depending upon the size and nature of the constituents attached to the thiol or alkene. A general thiol-ene coupling reaction mechanism is represented below:
- In accordance with the disclosure herein, a medical gel, such as a hydrogel, is provided with a plurality of reactive members of a specific binding pair attached on the surface of the gel or to precursor molecules which form the gel. As used herein, unless otherwise specified, “attached to the surface of the gel” or “attached on the surface of the gel” or “located on the gel” is intended to include attachment to molecules which are precursors of the gel. When the reactive members of the medical gel are contacted with biological tissue containing complementary reactive members of the specific binding pair, covalent attachment occurs, thus adhering the gel to the tissue. In embodiments, the reactive members may be either a dipolarophile or a 1,3 dipolar compound depending on which complement is applied to the target tissue or the medical gel. For example, if a dipolarphile is located on the gel, the 1,3 dipolar compound will be located on the tissue. If a dipolarphile is located on the tissue, the 1,3 dipolar compound will be located on the gel. In embodiments, the Diels-Alder members of a specific binding pair may be either a diene and a dienophile depending on which complement is applied to the target tissue or the medical gel. For example, if a diene is located on the gel, the dienophile can be located on the tissue. If a diene is located on the tissue, the dienophile can be located on the gel. In embodiments, the thiol-ene members of a specific binding pair may be either a thiol and an alkene depending on which complement is applied to the target tissue or the gel. For example, if a thiol is located on the gel, the alkene can be located on the tissue. If a thiol is located on the tissue, the alkene can be located on the gel.
- The medical gel may be biocompatible and absorbable or biocompatible and non-absorbable. In one embodiment, the reactive members are attached directly to the polymeric backbone of the gel. In another embodiment, the reactive members are attached to the polymeric backbone via a cross-linker. Cross-linkers are discussed below. Hydrogels can be formed, e.g., when an organic polymer, also referred to herein as precursor molecules which form the gel, which can be natural or synthetic, is set or at least partially solidified to create a three-dimensional open-lattice structure that entraps molecules of water or other solutions to form a gel. Hydrogels have an affinity for water and typically swell in water, but do not necessarily dissolve in water. Solidification can occur by aggregation, coagulation, hydrophobic interactions, cross-linking, or similar means. In certain embodiments, hydrogels are formed by polymerization and crosslinking of a hydrophilic monomer in an aqueous solution to cause the solution to gel. In embodiments, the hydrogel is composed of 85% water, to which can be added any salt or adjuvant.
- Hydrogels may be organic gels or inorganic gels. Organic gels from which the hydrogel of the invention can be selected include, by way of example and not by way of limitation, gels formed from polysaccharides and mucopolysaccharides including, but not limited to hyaluronic acid, dextran, heparin sulfate, chondroitin sulfate, agar, starch, and alginate; proteins, including but not limited to, fibronectin, gelatin, collagen, fibrin, chitosan, chitin, pectins, albumin, ovalbumin, and polyamino acids; collagen-hydroxyethyl-methacrylate (HEMA); polyphosphazines; polyphosphoesters; polyethylene glycol; polyethylene oxide; polyvinyl alcohol; polyvinylpyrrolidone; polyethyloxazoline; polyethylene oxide-co-polypropyleneoxide block copolymers; PGA-PEG-PGA block copolymers; PGA-PEG diblock copolymers; acrylates, including but not limited to diacrylates, oligoacrylates, methacrylates, dimethacrylates and oligomethacrylates; PEG-oligoglycolylacrylates; polyacrylonitriles (PAN); carboxy alkyl celluloses, including but not limited to carboxymethyl cellulose; partially oxidized cellulose; biodegradable polymers including but not limited to polymers and oligomers of glycolide, lactide, polyesters of α-hydroxy acids, including lactic acid and glycolic acid, such as the poly(α-hydroxy) acids including polyglycolic acid, poly-DL-lactic acid, poly-L-lactic acid, and terpolymers of DL-lactide and glycolide; ε-caprolactone and ε-caprolactone copolymerized with polyesters; polylactones and polycaprolactones including poly(ε-caprolactone), poly(δ-valerolactone) and poly(γ-butyrolactone); polyanhydrides; polyorthoesters; polydioxanone; and other biologically degradable polymers that are non-toxic or are present as metabolites in the body; as well as non-degradable polymers such as styrene and acrolein.
- Collagen-hydroxyethyl-methacrylate (EMA) hydrogel polymer is commonly formed from a gelled and crosslinked hydrophilic monomer solution to form a three dimensional polymeric meshwork anchoring macromolecules. Crosslinking of the hydrophilic monomer solution can be accomplished by free radical polymerization of hydrophilic monomers, such as hydroxyethyl-methacrylate (HEMA). Hydrogel polymers formed by free radical polymerization of monomer solutions require crosslinking to form the three dimensional network to gel the aqueous solution. HEMA monomer solutions typically can be crosslinked to gel by dimethacrylate, although other crosslinking agents, such as ethylene glycol dimethacrylate or methylmethacrylate, can also be used during polymerization to modify the hydrogel. A wide variety of other hydrophilic monomers may also be suitable for purposes of the invention. Inorganic gels include, by way of example and not by way of limitation, silica, alumina, and ferric oxide.
- Bulk and cellular hydrogels may be prepared by covalent cross linking or physical cross linking of the hydrogel molecules. Thus, covalent cross linking, also known as chemical cross linking, includes the use of multi-functional reactive chemical molecules such as aldehydes, maleic acid, dimethyl urea, di-isocyanates, boric acid, and the like, and also the use of ionizing radiation, ultraviolet light, and the like, while physical cross linking methods, also known as reversible cross linking, includes cross linking through crystallites, hydrogen bonding and complexing agents such as titanium, aluminum, manganese, and copper, to name a few. Physical cross linking through formation of crystallites in, e.g., polyvinyl alcohols, chitosan and the like, using, for example, partial freeze-drying, repeated freezing and thawing, low temperature crystallization, physical cross linking induced by the presence of aqueous solutions of organic compounds, salts, acids and bases and the like.
- In the present application, the term “bioresorbable” and “bioabsorbable” are used interchangeably and are intended to mean the characteristic according to which an implant and/or a material is resorbed by the biological tissues and the surrounding fluids and disappears in vivo after a given period of time, that may vary, for example, from one day to several months, depending on the chemical nature of the implant and/or of the material. Non bioresorbable material—also called permanent material—is not substantially resorbed by tissues and surrounding fluids, after 2 years and more, keeping in particular most (e.g., >80%) of their mechanical properties after such a time. The term “biocompatible” is intended to mean the characteristic according to which an implant and/or a material is well integrated by the biological tissues and the surrounding fluids without inducing excessive inflammation reaction around the bulk of the material or due to its degradation. The material should avoid also the formation of a fibrous capsule which usually results in the delay of the cellular integration of a porous implant.
- Many of the above described examples of polymers do not contain functional groups in their molecules. In embodiments, the reactive members are attached to the medical gel by surface modification techniques such as plasma treatment, silane coupling treatment and acid sensitization. Surface activation of the medical gel can be achieved by acid or base hydrolysis, treatment by means of cold plasma, by chemical reactions or electromagnetic radiations.
- Hydrolysis can be conducted in the presence of an aqueous solution of a base or an acid to accelerate surface reaction, inasmuch as excessively long processes of activation can induce a reduction in molecular weight and thus in the mechanical properties of the material. Suitable bases for obtaining watery solutions suited to the aim are, for example, strong alkalis, such as LiOH, Ba(OH)2, Mg(OH)2, NaOH, KOH, Na2CO3, Ca(OH)2 and the weak bases, such as for example NH4OH and the amines such as methylamine, ethylamine, diethylamine and dimethylamine. Acids suitable for surface hydrolysis treatments can be chosen, for example, from among HCl, HClO3, HClO4, H2SO3, H2SO4, H3PO3, H3PO4, HI, HIO3, HBr, lactic acid, glycolic acid. Surface activation by means of hydrolysis can be conducted at temperatures preferably comprised between 0 degrees Celsius and the material softening temperature.
- Plasma treatment can be carried out both in the presence of a reactive gas, for example air, Ar, O2 with the formation of surface activation of oxygenate type, such as —OH, —CHO, —COOH.
- Surface treatment, whether hydrolytic or with plasma, can remain unaltered or can be followed by further chemical modifications to provide the first reactive groups on the bioabsorbable polymeric substrate. Thus, for example, the COONa groups generated by a base hydrolysis can be subsequently converted into COOH groups by treatment with strong mineral acids. Further, the surface freeing of alcoholic groups by means of a hydrolysis process can be followed by reaction by means of the addition of a compound provided with functional group or groups able to react with surface alcoholic groups, such as for example by means of the addition of an anhydride such as succinic anhydride, with the conversion of —OH groups into —O—CO—CH2—CH2—COOH groups. Suitable surface activation techniques are disclosed in U.S. Pat. No. 6,107,453, the entire disclosure of which is incorporated herein by this reference.
- During manufacture of polymers, pendant functional groups can be incorporated into the polymer backbone by, e.g., copolymerization with functionalized monomer such as lactones, cyclic carbonates and morpholine-2,5-diones. The azido group, N3 is a nucleophilic group that will exchange with other nucleophilic groups, e.g., —OH, —NH2 and halogens (Br, Cl, or I). For example, 1,3-dipolar compounds may be conjugated to aliphatic polyesters, by copolymerizing, e.g., ε-caprolactone and α-chloro-ε-caprolactone and then substituting an azide group for the Cl atom. Polyesters can incorporate pendant dipolarophiles, e.g., propargyl groups, by copolymerization of ε-caprolactone and α-propargyl-δ-valerolactone. Copolymers of L-lactide containing propargyl groups may, e.g., be prepared by ring opening copolymerization of 5-methyl-5-propargyloxycarbonyl-1,3-dioxanone with L-lactide at a molar ratio of about 90:10 with ZnEt2 as a catalyst. See, Shi et al., Biomaterials, 29 (2008)1118-1126. Azide functionalized polystyrene is synthesized using atom transfer radical polymerization and subsequent modification with azidotrimethylsilane and tetrabutylammonium fluoride. See, Dirks, et al., Chem. Comm., (2005) 4172-4174. Azides may be incorporated onto methacrylates, e.g., 3 azidopropyl methacrylate which is copolymerized to a block copolymer. Diels-Alder functionalities and thiol-ene functionalities are likewise incorporated into polymers herein.
- Biological tissue is provided with reactive members or complementary reactive members of a specific binding pair by conjugation to various components of tissue such as proteins, lipids, oligosaccharides, oligonucleotides, glycans, including glycosaminoglycans. In one embodiment, the reactive members or complementary reactive members are attached directly to components of the tissue. In another embodiment, the reactive members or complementary reactive members are attached to components of the tissue via a linker. In either case, situating the reactive members or complementary reactive members on the tissue can be accomplished by suspending the reactive members or complementary reactive members in a solution or suspension and applying the solution or suspension to the tissue such that the reactive member or complementary reactive members binds to a target. The solution or suspension may be poured, sprayed or painted onto the tissue, whereupon the reactive members are incorporated into the tissue.
- 1,3-Dipolar compounds can be incorporated into proteins, lipids, oligosaccharides, oligonucleotides and glycans using, e.g., metabolic machinery, covalent inhibitors and enzymatic transfers. For example, an azido group, N3, can be applied at the N-terminus of proteins or peptides using azidoacetyl chloride. See, e.g., Haridas, et al., Tetrahedron Letters 48 (2007) 4719-4722. The azido group is a nucleophilic group that will exchange with other nucleophilic groups, e.g., —OH, —NH2 and halogens (Br, Cl, or I). NaN3 is an azidizing agent which is capable of aziding proteins by simply contacting the proteins with a 10 times molar excess of NaN3. A process for C-terminal azidization is described in Cazalis, et al., Bioconjugate Chem., 15 (2004) 1005-1009. Incubation of cells with peracetylated N-azidoacetylmannosamine provides cell surface glycans with azido sialic acid. See, e.g., Codelli et al., J. Amer. Chem. Soc., 130 (34) 11486-11493 (2008). Azido-tagged lipids are described in Smith, et al., Bioconjugate Chem., 19 (9), 1855-1863 (2008). PEGylation is a commonly used technique for adding groups to peptides and proteins and is suitable for use herein. For example, PEG may be covalently bound to amino acid residues via a reactive group. Reactive groups (as opposed to reactive members herein) are those to which an activated PEG molecule may be bound (e.g., a free amino or carboxyl group). For example, N-terminal amino acid residues and lysine (K) residues have a free amino group and C-terminal amino acid residues have a free carboxyl group. Sulfhydryl groups (e.g., as found on cysteine residues) may also be used as a reactive group for attaching PEG. In addition, enzyme-assisted methods for introducing activated groups (e.g., hydrazide, aldehyde, and aromatic-amino groups) specifically at the C-terminus of a polypeptide. Accordingly, PEG incorporating 1,3-dipolar compounds may be utilized herein Those skilled in the art can utilize any known process for coupling a 1,3-dipolar compound into proteins, lipids, oligosaccharides, oligonucleotides and glycans.
- Dipolarophile functionalized proteins and peptides can be synthesized by linking at the N-terminus with, for example, an alkyne (e.g., 3 butynyl chloroformate), in connection with a tripeptide (GlyGlyArg). See, Dirks, et al., supra. A suitable tripeptide herein is the well-known cell adhesion sequence RGD. It should be understood that, as used herein, “proteins” is intended to encompass peptides and polypeptides. In one embodiment, thiols on cysteines are functionalized with alkyne bearing maleimide. Id. Providing a C-terminal dipolarophile can be accomplished, e.g., by coupling with propargylamine using a cross-linking agent such as N-hydroxysuccinimide/DCC. See, e.g., Haridas, et al. supra. Terminal alkynes can be installed using metabolic building blocks such as alkynoic acids. Lipids may be functionalized with alkynes. For example, alkyne modified fatty acids can be generated by reaction of terminal alkynyl-alkyl bromide with trimethyl phosphine to yield a 16-carbon alkynyl-dimethylphosphonate. See, e.g., Raghavan et al., Bioorg. Med. Chem. Lett., 18 (2008) 5982-5986. As above, PEGylation may be used for adding dipolarophile groups to peptides and proteins and is suitable for use herein. Diels-Alder functionalities and thiol-ene functionalities are likewise attached to proteins, lipids, oligosaccharides, oligonucleotides and glycans.
- The reactive members or complementary reactive members may be also attached to biological tissue or the medical gel via a linker. In certain embodiments, the linker is or includes a ligand which bears a reactive member. The ligand binds to a desired target on the tissue and thus provides a vehicle for transporting and indirectly binding the reactive member or complementary reactive member to the tissue. The ligand herein is any molecule or combination of molecules which demonstrates an affinity for a target. Examples of ligands include nucleic acid probes, antibodies, hapten conjugates, and cell adhesion peptides such as RGD. The mechanisms involved in obtaining and using such ligands are well-known. In embodiments, reactive members or complementary reactive members are incorporated into saccharides or polysaccharides and metabolically incorporated into cells. See, e.g., Baskin et al., supra.
- Antibodies that specifically recognize antigens are useful in accordance with one embodiment herein. Antibodies which are conjugated to a reactive member or complementary reactive members are utilized to bind to proteins located on tissue. Monoclonal or polyclonal antibodies are raised against an antigen which can be any component of biological tissue and then purified using conventional techniques. The term “antibody” is intended to include whole antibodies, e.g., of any isotype (IgG, IgA, IgM, IgE, etc.), and to include fragments thereof which are also specifically reactive with a vertebrate, e.g., mammalian, protein. Antibodies may be fragmented using conventional techniques and the fragments screened for utility in the same manner as for whole antibodies. Thus, the term includes segments of proteolytically-cleaved or recombinantly-prepared portions of an antibody molecule that are capable of selectively reacting with a certain protein. Non-limiting examples of such proteolytic and/or recombinant fragments include Fab, F(ab′)2, Fab′, Fv, and single chain antibodies (scFv) containing a V[L] and/or V[H] domain joined by a peptide linker. The scFv's may be covalently or non-covalently linked to form antibodies having two or more binding sites. The present disclosure includes polyclonal, monoclonal or other purified preparations of antibodies and recombinant antibodies.
- After purification, the ligands (e.g., antibodies, nucleic acid probes, hapten conjugates and cell adhesion peptides), are conjugated or linked to reactive members or complementary reactive members in the manners described above. In addition, reactive members or complementary reactive members can be linked to ligands by cross-linking procedures which, in accordance with the present invention, do not cause denaturing or misfolding of the ligands. The terms “linked” or “conjugated” as used herein are used interchangeably and are intended to include any or all of the mechanisms known in the art for coupling the reactive members or complementary reactive members to the ligand. For example, any chemical or enzymatic linkage known to those with skill in the art is contemplated including those which result from photoactivation and the like. Homofunctional and heterobifunctional cross linkers are all suitable. Reactive groups (distinguishable from reactive members or complementary reactive members herein) which can be cross-linked with a cross-linker include primary amines, sulfhydryls, carbonyls, carbohydrates and carboxylic acids.
- Cross-linkers are conventionally available with varying lengths of spacer arms or bridges. Cross-linkers suitable for reacting with primary amines include homobifunctional cross-linkers such as imidoesters and N-hydroxysuccinimidyl (NHS) esters. Examples of imidoester cross-linkers include dimethyladipimidate, dimethylpimelimidate, and dimethylsuberimidate. Examples of NHS-ester cross-linkers include disuccinimidyl glutamate, disucciniminidyl suberate and bis(sulfosuccinimidyl) suberate. Accessible amine groups present on the N-termini of peptides react with NHS-esters to form amides. NHS-ester cross-linking reactions can be conducted in phosphate, bicarbonate/carbonate, HEPES and borate buffers. Other buffers can be used if they do not contain primary amines. The reaction of NHS-esters with primary amines should be conducted at a pH of between about 7 and about 9 and a temperature between about 4° C. and 30° C. for about 30 minutes to about 2 hours. The concentration of NHS-ester cross-linker can vary from about 0.1 to about 10 mM. NHS-esters are either hydrophilic or hydrophobic. Hydrophilic NHS-esters are reacted in aqueous solutions although DMSO may be included to achieve greater solubility. Hydrophobic NHS-esters are dissolved in a water miscible organic solvent and then added to the aqueous reaction mixture.
- Sulfhydryl reactive cross-linkers include maleimides, alkyl halides, aryl halides and a-haloacyls which react with sulfhydryls to form thiol ether bonds and pyridyl disulfides which react with sulfhydryls to produce mixed disulfides. Sulfhydryl groups on peptides and proteins can be generated by techniques known to those with skill in the art, e.g., by reduction of disulfide bonds or addition by reaction with primary amines using 2-iminothiolane. Examples of maleimide cross-linkers include succinimidyl 4-{N-maleimido-methyl)cyclohexane-1-carboxylate and m-maleimidobenzoyl-N-hydroxysuccinimide ester. Examples of haloacetal cross-linkers include N-succinimidyl(4-iodoacetal)aminobenzoate and sulfosuccinimidyl(4-iodoacetal)aminobenzoate. Examples of pyridyl disulfide cross-linkers include 1,4-Di-[3′-2′-pyridyldithio(propionamido)butane] and N-succinimidyl-3-(2-pyridyldithio)-propionate.
- Carboxyl groups are cross-linked to primary amines or hydrazides by using carbodimides which result in formation of amide or hydrazone bonds. In this manner, carboxy-termini of peptides or proteins can be linked. Examples of carbodiimide cross-linkers include 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride and N, N1-dicyclohexylcarbodiimide. Arylazide cross-linkers become reactive when exposed to ultraviolet radiation and form aryl nitrene. Examples of arylazide cross-linkers include azidobenzoyl hydrazide and N-5-azido-2 nitrobenzoyloxysuccinimide. Glyoxal cross linkers target the guanidyl portion of arginine. An example of a glyoxal cross-linker is p-azidophenyl glyoxal monohydrate.
- Heterobifunctional cross-linkers which possess two or more different reactive groups are suitable for use herein. Examples include cross-linkers which are amine-reactive at one end and sulfhydryl-reactive at the other end such as 4-succinimidyl-oxycarbonyl-a-(2-pyridyldithio)-toluene, N-succinimidyl-3-(2-pyridyldithio)-propionate and the maleimide cross-linkers discussed above.
- Attachment of reactive members or complementary reactive members to the medical gel functionalizes the gel such that upon exposure to their complementary reactive members which are situated on tissue, they are activated and form a covalent bond, thus adhering the gel to the tissue. In one embodiment, a linker between the product of the reactive members or complementary reactive members and the biological tissue is degradable by, e.g., hydrolysis or enzymatic action. In this manner, the medical gel can be removable after a period of time. The degradable linkage may be chelates or chemically or enzymatically hydrolyzable or absorbable. Illustrative chemically hydrolyzable degradable linkages include polymers, copolymers and oligomers of glycolide, dl-lactide, 1-lactide, caprolactone, dioxanone, and tritnethylene carbonate. Illustrative enzymatically hydrolyzable biodegradable linkages include peptidic linkages cleavable by metalloproteinases and collagenases and chitosan cleavable by lysozyme. Additional illustrative degradable linkages include polymers and copolymers of poly(hydroxy acid)s, poly(orthocarbonate)s, poly(anhydride)s, poly(lactone)s, poly(amino acid)s, poly(carbonate)s, poly(saccharide)s and poly(phosphonate)s. In certain embodiments, the degradable linkage may contain ester linkages. Some non-limiting examples include esters of succinic acid, glutaric acid, propionic acid, adipic acid, or amino acids, as well as carboxymethyl esters.
- The ligand solution and gel can be sterilized by any known method, e.g., irradiation, ethylene oxide, filtration in sterile conditions on a 0.22 um filter and the like.
- Medical gels herein may be used in a variety of applications. In one embodiment, the gel is an uncured liquid, functionalized with a plurality of reactive members of a binding pair, which is applied and cured as a layer on surfaces of internal organs or tissues which were pretreated with the complementary reactive member as described above. The target tissue is pretreated by spraying, painting or pouring a solution or suspension containing the complementary reactive members of a binding pair on to the tissue. Ligands associated with the reactive members or complementary reactive members bind to their predetermined targets on the tissue, thereby anchoring the reactive members or complementary reactive members on the tissue. The uncured functionalized liquid gel is sprayed over, e.g., a defect on the tissue where it cures while simultaneously, the reactive members and complementary reactive members of the specific binding pair react specifically together to form covalent bonds, providing adhesion between the tissue and the curing or cured gel. In another embodiment, the functionalized gel is cured prior to application to pretreated tissue and then draped over or otherwise contacted with the target or defect to allow the covalent bond forming reaction to occur with consequent covalent bonding and adherence. In certain embodiments, two opposing tissue surfaces are pretreated and functionalized, and functionalized gel added to form bonds to both opposing surfaces.
- Some applications include using the medical gel composition to bind tissue together either as an adjunct to or as a replacement of sutures, staples, tapes and/or bandages. In another application, the present gels may be used to prevent post-surgical adhesions. In this application, the gel, functionalized with a reactive member of a binding pair, is applied and cured as a layer on surfaces of internal organs or tissues which were pretreated with a complementary reactive member of the binding pair as described above in order to prevent the formation of adhesions at a surgical site as the site heals. In another application, the functionalized gel may be used to attach pretreated skin grafts and to position pretreated tissue flaps or free flaps during reconstructive surgery. In still another application, the functionalized gel may be used to close pretreated gingival flaps in periodontal surgery. Additional applications include sealing tissues to prevent or control blood or other fluid leaks at suture or staple lines as well as to prevent or control air leaks in the pulmonary system.
- In addition, functionalized medical gels herein can be used as bulking agents, e.g., they can be injected via a syringe and needle or other generally accepted means directly into a specific area wherever a bulking agent is desired, i.e., a pretreated soft tissue deformity such as that seen with areas of muscle atrophy due to congenital or acquired diseases or secondary to trauma, burns, and the like. An example of this would be the injection of a medical gel herein in the upper torso of a patient with muscular atrophy secondary to nerve damage. A medical gel herein can also be injected as a bulking agent for hard tissue defects, such as bone or cartilage defects, either congenital or acquired disease states, or secondary to trauma, burns, or the like. An example of this would be an injection into the area surrounding the skull where a bony deformity exists secondary to trauma. The injection in these instances can be made directly into the needed area with the use of a needle and syringe under local or general anesthesia.
- A medical gel could also be injected percutaneously by direct palpation, such as by placing a needle inside a pretreated vas deferens and occluding the same with the injected functionalized bulking medical gel, thus rendering the patient infertile. The gel could also be injected through a catheter or needle with fluoroscopic, sonographic, computed tomography, magnetic resonance imaging or other type of radiologic guidance. This would allow for placement or injection of the pretreatment formulation and subsequent functionalized medical gel either by vascular access or percutaneous access to specific organs or other tissue regions in the body, wherever a bulking agent would be required.
- Techniques of tissue engineering employing functionalized medical gel scaffolds can be used to create alternatives to prosthetic materials currently used in craniomaxillofacial surgery, as well as formation of organ equivalents to replaced diseased, defective, or injured tissues. Medical gels herein can be malleable and used to encapsulate cells. To form a hydrogel containing the cells, a functionalized polymer solution is mixed with the cells to be implanted to form a suspension. Then, in one embodiment, the target site is pretreated with complementary members of a specific binding pair and the functionalized polymers in suspension are injected directly into a patient prior to crosslinking of the polymer to form the hydrogel containing the cells. The hydrogel cures over a short period of time while simultaneously binding to the pretreated area through covalent bond formation. In another embodiment, the functionalized gel is injected or poured into a mold, where it crosslinks to form a semi-solid hydrogel of the desired anatomical shape having cells dispersed therein which then may be implanted in a pretreated target area in a patient. The hydrogel may be produced, for example, by cross-linking a polysaccharide polymer by exposure to a monovalent cation. Other polymers capable of forming functionalized hydrogels as described above may be used as disclosed herein. In the embodiments where the functionalized polymer is crosslinked by contact with a crosslinking agent, the strength of the crosslink may be increased or reduced by adjusting the concentration of the polymer and/or crosslinking agent.
- Further, combinations in accordance with this disclosure, e.g., functionalized medical gel having reactive members of a specific binding pair and functionalized pretreatment formulation containing complementary members of the specific binding pair, could be injected through a laparoscope or thoracoscope to any intraperitoneal or extraperitoneal or thoracic organ. For example, the functionalized pretreatment formulation and functionalized gel could be injected in the region of the gastroesophageal junction for the correcting of gastroesophageal reflux. This could be performed either with a thoracoscope injecting the substances in the esophageal portion of the gastroesophageal region, or via a laparoscope by injecting the substances in the gastric portion of the gastroesophageal region, or by a combined approach.
- A kit for a functionalized adhesive herein includes a medical gel which has a plurality of reactive members of a specific binding pair adapted to be attached to a surface of the gel and an applicator adapted to contain a solution or suspension of complementary reactive members of the specific binding pair, the complementary reactive members having a functionality that will adhere them to biological tissue upon contact. The kit may optionally include a container which contains a catalyst for causing the reactive members of a specific binding pair to bind with the complementary reactive members of the specific binding pair. The catalyst may be a solution of metal such as copper. In embodiments, the kit contains a microwave or ultraviolet radiation generator.
- It should be understood that variations can be made to the above embodiments that are with the purview of ordinary skill in the art. For example, other click chemistry reactions are suitable for use herein, e.g., staudinger reaction of phosphines with alkyl azides. Accordingly, those skilled in the art can envision modifications which are included within the scope of the claimed invention that are not expressly set forth herein.
Claims (17)
1. A bioadherent substrate comprising a medical gel or medical gel precursor having a plurality of reactive members of a specific binding pair adapted to be attached on a surface of the medical gel, said reactive members being capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair via a reaction selected from the group consisting of Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction.
2. The bioadherent substrate according to claim 1 wherein the medical gel is a hydrogel.
3. The bioadherent substrate according to claim 1 wherein the plurality of reactive members of the specific binding pair are selected from the group consisting of alkynes and azides.
4. The bioadherent substrate according to claim 1 wherein the plurality of reactive members of the specific binding pair form covalent bonds via a reaction catalyzed by copper to activate an alkyne and an azide for [3+2] cycloaddition.
5. The bioadherent substrate according to claim 1 wherein the plurality of reactive members of the specific binding pair form covalent bonds via a reaction involving a cyclooctyne reagent and an azide for [3+2] cycloaddition.
6. The bioadherent substrate according to claim 1 wherein the plurality of reactive members of the specific binding pair are selected from the group consisting of thiols and alkenes.
7. The bioadherent substrate according to claim 1 wherein the plurality of reactive members of the specific binding pair are selected from the group consisting of dienes and alkenes.
8. The bioadherent substrate according to claim 1 wherein the medical gel is made of a polymer selected from the group consisting of polysaccharides, mucopolysaccharides, polyaminoacids, proteins, collagen-hydroxyethyl-methacrylate (HEMA), polyphosphazines, polyphosphoesters, polyethylene glycol, polyethylene oxide, polyvinyl alcohol, polyvinylpyrrolidone, polyethyloxazoline, polyethylene oxide-co-polypropyleneoxide block copolymers, PGA-PEG-PGA block copolymers, PGA-PEG diblock copolymers, acrylates, PEG-oligoglycolylacrylates, polyacrylonitriles (PAN), carboxy alkyl celluloses, poly(α-hydroxy) acids, polylactones, polycaprolactones, polyanhydrides, polyorthoesters, polydioxanone, styrene, acrolein and copolymers, block copolymers, homoploymers, blends and combinations thereof.
9. A bioadherent substrate capable of covalently binding to tissue, the bioadherent substrate comprising:
a hydrogel comprising a plurality of reactive members of a specific binding pair, the plurality of reactive members being present on a surface of the medical gel and capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair linked to tissue via a ligand-receptor linkage,
the hydrogel capable of forming covalent bonds via a reaction selected from the group consisting of Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction.
10. The bioadherent substrate according to claim 9 wherein the plurality of reactive members are attached directly to a polymeric backbone of the hydrogel.
11. The bioadherent substrate according to claim 9 wherein the hydrogel comprises a polymer selected from the group consisting of polysaccharides, mucopolysaccharides, polyaminoacids, proteins, collagen-hydroxyethyl-methacrylate (HEMA), polyphosphazines, polyphosphoesters, polyethylene glycol, polyethylene oxide, polyvinyl alcohol, polyvinylpyrrolidone, polyethyloxazoline, polyethylene oxide-co-polypropyleneoxide block copolymers, PGA-PEG-PGA block copolymers, PGA-PEG diblock copolymers, acrylates, PEG-oligoglycolylacrylates, polyacrylonitriles (PAN), carboxy alkyl celluloses, poly(α-hydroxy) acids, polylactones, polycaprolactones, polyanhydrides, polyorthoesters, polydioxanone, styrene, acrolein and copolymers, block copolymers, homoploymers, blends and combinations thereof.
12. The bioadherent substrate according to claim 9 wherein the hydrogel comprises a chemically cross linked polymer.
13. The bioadherent substrate according to claim 9 wherein the hydrogel is an uncured liquid.
14. The bioadherent substrate according to claim 9 wherein the hydrogel is configured to be draped over tissue having a plurality of complementary reactive members of the specific binding pair thereon.
15. The bioadherent substrate according to claim 9 wherein the hydrogel is injectable.
16. The bioadherent substrate according to claim 9 wherein the hydrogel comprises a layer configured to prevent formation of adhesions at a surgical site, the layer having a tissue contacting surface on which the plurality of reactive members are present.
17. A kit comprising
a functionalized medical gel or medical gel precursor having a plurality of reactive members of a specific binding pair adapted to be presented on a surface of the gel;
a container containing a mixture which may be a solution or suspension containing complementary reactive members of the specific binding pair, the complementary reactive members having a functionality that will adhere them to biological tissue upon contact; and
at least one applicator adapted to deliver the functionalized medical gel or medical gel precursor or the mixture to biological tissue.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/154,338 US20140128497A1 (en) | 2009-02-21 | 2014-01-14 | Functionalized adhesive medical gel |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15436909P | 2009-02-21 | 2009-02-21 | |
US12/708,828 US8663689B2 (en) | 2009-02-21 | 2010-02-19 | Functionalized adhesive medical gel |
US14/154,338 US20140128497A1 (en) | 2009-02-21 | 2014-01-14 | Functionalized adhesive medical gel |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/708,828 Division US8663689B2 (en) | 2009-02-21 | 2010-02-19 | Functionalized adhesive medical gel |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140128497A1 true US20140128497A1 (en) | 2014-05-08 |
Family
ID=42470865
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/708,828 Active 2031-07-27 US8663689B2 (en) | 2009-02-21 | 2010-02-19 | Functionalized adhesive medical gel |
US14/154,338 Abandoned US20140128497A1 (en) | 2009-02-21 | 2014-01-14 | Functionalized adhesive medical gel |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/708,828 Active 2031-07-27 US8663689B2 (en) | 2009-02-21 | 2010-02-19 | Functionalized adhesive medical gel |
Country Status (5)
Country | Link |
---|---|
US (2) | US8663689B2 (en) |
EP (2) | EP2606915B1 (en) |
AU (1) | AU2010215195B2 (en) |
CA (1) | CA2753177A1 (en) |
WO (1) | WO2010095048A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10155063B2 (en) | 2015-11-12 | 2018-12-18 | University Of Virginia Patent Foundation | Methods for vas-occlusive contraception and reversal thereof |
US10751124B2 (en) | 2017-01-05 | 2020-08-25 | Contraline, Inc. | Methods for implanting and reversing stimuli-responsive implants |
US11253391B2 (en) | 2018-11-13 | 2022-02-22 | Contraline, Inc. | Systems and methods for delivering biomaterials |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011090428A1 (en) * | 2010-01-19 | 2011-07-28 | Organoclick Ab | Heterogeneous thiol-ene click modifications of solid polysaccharide-based materials |
WO2011117745A2 (en) | 2010-03-25 | 2011-09-29 | Sofradim Production | Surgical fasteners and methods for sealing wounds |
EP2630196B1 (en) | 2010-10-20 | 2017-09-06 | Li-Cor, Inc. | Cyanine dyes and their conjugates |
US9499636B2 (en) * | 2012-06-28 | 2016-11-22 | Covidien Lp | Dissolution of oxidized cellulose and particle preparation by cross-linking with multivalent cations |
CN102772823A (en) * | 2012-07-25 | 2012-11-14 | 华南理工大学 | Preparation method of hyaluronic acid/gelatin/chondroitin sulfate bone repair bionic scaffold |
WO2014160083A1 (en) * | 2013-03-13 | 2014-10-02 | Applied Cardiovascular Solutions, Llc. | Methods, compositions, and devices for the occlusion of cavities and passageways |
JP6820857B2 (en) | 2015-02-20 | 2021-01-27 | メルク・ミリポア・リミテッド | Chromatographic film formed by thiol-ene or thiol-in-click polymerization reaction |
AU2019212513A1 (en) * | 2018-01-26 | 2020-09-03 | Fluidx Medical Technology, Llc | Apparatus and method of using in situ solidifying complex coacervates for vascular occlusion |
CN112957516B (en) * | 2018-08-20 | 2022-08-09 | 稳得希林(杭州)生物科技有限公司 | Polysaccharide-based tissue adhesive medical adhesive and application thereof |
CN112587723B (en) * | 2020-11-19 | 2021-12-17 | 南京医科大学 | In-situ rapid-forming magnetic hydrogel for repairing urinary system and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050089578A1 (en) * | 2001-02-05 | 2005-04-28 | Werkmeister Jerome A. | Methods and devices for tissue repair |
US20090226499A1 (en) * | 2008-03-03 | 2009-09-10 | New York University | Biocompatible materials containing stable complexes of tsg-6 and hyaluronan and method of using same |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3767085A (en) * | 1971-08-02 | 1973-10-23 | J Cannon | Mixing syringe |
AT366916B (en) | 1980-04-02 | 1982-05-25 | Immuno Ag | DEVICE FOR APPLICATING A TISSUE ADHESIVE BASED ON HUMAN OR ANIMAL PROTEINS |
US4361055A (en) | 1980-05-19 | 1982-11-30 | Juris Murnieks | Torque converter |
IT1144925B (en) | 1981-10-08 | 1986-10-29 | Anic Spa | CHITOSAN QUARRY FIBERS AND PROCEDURE FOR THEIR OBTAINING |
US4538920A (en) * | 1983-03-03 | 1985-09-03 | Minnesota Mining And Manufacturing Company | Static mixing device |
US4839345A (en) * | 1985-03-09 | 1989-06-13 | Nippon Oil And Fats Co., Ltd. | Hydrated adhesive gel and method for preparing the same |
US4861527A (en) | 1986-12-16 | 1989-08-29 | Delucca George V | High strength chitosan fibers and fabrics thereof |
US4857403A (en) * | 1986-12-16 | 1989-08-15 | E. I. Du Pont De Nemours And Company | High strength fibers from chitin derivatives |
DE3702999C2 (en) | 1987-02-02 | 2003-03-06 | Siemens Ag | Apparatus for processing UV-curable reaction resin compositions and their use |
US4753536A (en) * | 1987-03-09 | 1988-06-28 | Spehar Edward R | Dispensing mixer for the storage and mixing of separate materials |
US4978336A (en) | 1987-09-29 | 1990-12-18 | Hemaedics, Inc. | Biological syringe system |
US4874368A (en) * | 1988-07-25 | 1989-10-17 | Micromedics, Inc. | Fibrin glue delivery system |
US4979942A (en) | 1989-10-16 | 1990-12-25 | Johnson & Johnson Medical, Inc. | Two component syringe delivery system |
SE500503C2 (en) | 1990-12-07 | 1994-07-04 | Inst Polymerutveckling Ab | Method and irradiation unit for continuous cross-linking of polyethylene |
US5368563A (en) | 1991-12-18 | 1994-11-29 | Micromedics, Inc. | Sprayer assembly for physiologic glue |
US5372585A (en) | 1992-04-09 | 1994-12-13 | Tiefenbrun; Jonathan | Instrument and associated method for applying biologically effective composition during laparoscopic operation |
WO1994021324A1 (en) | 1993-03-23 | 1994-09-29 | Focal, Inc. | Apparatus and method for local application of polymeric material to tissue |
US5582955A (en) | 1994-06-23 | 1996-12-10 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Chemical functionalization of surfaces |
US5578662A (en) | 1994-07-22 | 1996-11-26 | United States Surgical Corporation | Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom |
US5562946A (en) * | 1994-11-02 | 1996-10-08 | Tissue Engineering, Inc. | Apparatus and method for spinning and processing collagen fiber |
US6107453A (en) * | 1995-07-28 | 2000-08-22 | Sanitaria Scaligera S.P.A. | Process of surface activation of biocompatible and bioabsorbable aliphatic polyesters and polyesters thus activated |
US5911942A (en) * | 1995-11-02 | 1999-06-15 | Tissue Engineering, Inc. | Method for spinning and processing collagen fiber |
FR2766717B1 (en) * | 1997-08-01 | 2000-06-09 | Cogent Sarl | COMPOSITE PROSTHESIS FOR PREVENTION OF POST-SURGICAL ADHESIONS AND PROCESS FOR OBTAINING SAME |
JP4330268B2 (en) * | 1997-09-03 | 2009-09-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Novel biomimetic hydrogel materials |
CA2222837A1 (en) * | 1997-11-28 | 1999-05-28 | Brent R. Stranix | Cycloaddition functional polymers from (vinyl)polystyrene |
ES2346679T3 (en) * | 1997-12-19 | 2010-10-19 | Tyco Healthcare Group Lp | TWO COMPONENT DISPENSING SYSTEM. |
US7534866B2 (en) * | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US6423818B1 (en) | 1999-07-30 | 2002-07-23 | Takehisa Matsuda | Coumarin endcapped absorbable polymers |
AU2001281463A1 (en) * | 2000-03-16 | 2001-09-24 | The Regents Of The University Of California | Chemoselective ligation |
SG106615A1 (en) * | 2000-06-30 | 2004-10-29 | Sumitomo Chemical Co | Polypropylene resin composition, t die film made of the same and method of producing t die film |
AU8298201A (en) * | 2000-08-17 | 2002-02-25 | Tyco Healthcare | Sutures and coatings made from therapeutic absorbable glass |
US6576000B2 (en) * | 2001-03-06 | 2003-06-10 | Scimed Life Systems, Inc. | Devices and methods for tissue repair |
US6808908B2 (en) * | 2001-05-30 | 2004-10-26 | Porex Technologies Corporation | Functionalized porous substrate for binding chemical and biological moieties |
US7012629B2 (en) * | 2001-09-25 | 2006-03-14 | Fuji Photo Film Co., Ltd. | Temperature compensating image recording device |
US7294357B2 (en) | 2001-09-28 | 2007-11-13 | Tyco Healthcare Group Lp | Plasma coated sutures |
US8501165B2 (en) * | 2001-12-12 | 2013-08-06 | Promethean Surgical Devices Llc | In situ bonds |
US7371719B2 (en) * | 2002-02-15 | 2008-05-13 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
US8877901B2 (en) * | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US7591994B2 (en) * | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US7585491B2 (en) * | 2002-12-13 | 2009-09-08 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
WO2003092746A1 (en) | 2002-05-03 | 2003-11-13 | Gambro, Inc. | Fluid mixing and irradiation device and method of using the device especially for biological fluids |
DK2226316T3 (en) * | 2002-05-30 | 2016-04-11 | Scripps Research Inst | Copper catalyzed ligation of azides and acetylenes |
US8016881B2 (en) * | 2002-07-31 | 2011-09-13 | Icon Interventional Systems, Inc. | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
US20050032081A1 (en) * | 2002-12-13 | 2005-02-10 | Jingyue Ju | Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry |
US7172877B2 (en) * | 2003-01-09 | 2007-02-06 | Massachusetts Institute Of Technology | Methods and compositions for peptide and protein labeling |
US20050233389A1 (en) * | 2003-01-09 | 2005-10-20 | Massachusetts Institute Of Technology | Methods and compositions for peptide and protein labeling |
WO2004075943A1 (en) * | 2003-02-28 | 2004-09-10 | Biointeractions Ltd. | Polymeric network system for medical devices and methods of use |
WO2005062854A2 (en) | 2003-12-19 | 2005-07-14 | University Of Cincinnati | Polyamides for nucleic acid delivery |
WO2005079217A2 (en) | 2003-12-19 | 2005-09-01 | University Of Cincinnati | Oligonucleotide decoys and methods of use |
WO2006107617A2 (en) | 2005-04-06 | 2006-10-12 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
WO2007021762A2 (en) | 2005-08-09 | 2007-02-22 | The University Of North Carolina At Chapel Hill | Methods and materials for fabricating microfluidic devices |
US7833978B2 (en) * | 2004-02-20 | 2010-11-16 | Emory University | Thrombomodulin derivatives and conjugates |
US7622279B2 (en) | 2004-03-03 | 2009-11-24 | The Trustees Of Columbia University In The City Of New York | Photocleavable fluorescent nucleotides for DNA sequencing on chip constructed by site-specific coupling chemistry |
WO2005087818A1 (en) | 2004-03-05 | 2005-09-22 | Carnegie Mellon University | Preparation of functional polymers |
US7985424B2 (en) | 2004-04-20 | 2011-07-26 | Dendritic Nanotechnologies Inc. | Dendritic polymers with enhanced amplification and interior functionality |
KR100843362B1 (en) | 2004-04-20 | 2008-07-02 | 덴드리틱 나노테크놀로지즈, 인크. | Dendritic polymers with enhanced amplification and interior functionality |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
US20060018948A1 (en) * | 2004-06-24 | 2006-01-26 | Guire Patrick E | Biodegradable implantable medical devices, methods and systems |
US20080138317A1 (en) * | 2004-06-30 | 2008-06-12 | Ramie Fung | Use of biocompatible amphiphilic polymers as an anti-inflammatory agent |
CN101006119A (en) | 2004-06-30 | 2007-07-25 | 斯克里普斯研究学院 | Click chemistry route to triazole dendrimers |
US8101238B2 (en) | 2004-07-22 | 2012-01-24 | The Scripps Research Institute | Polymeric materials via click chemistry |
US7247692B2 (en) * | 2004-09-30 | 2007-07-24 | Johnson & Johnson Vision Care, Inc. | Biomedical devices containing amphiphilic block copolymers |
US7717313B2 (en) * | 2004-10-18 | 2010-05-18 | Tyco Healthcare Group Lp | Surgical apparatus and structure for applying sprayable wound treatment material |
AU2005295477B2 (en) * | 2004-10-18 | 2011-11-24 | Covidien Lp | Structure for applying sprayable wound treatment material |
ES2545533T3 (en) | 2004-11-01 | 2015-09-11 | The Regents Of The University Of California | Compositions and methods for biomolecule modification |
US20060147963A1 (en) * | 2004-12-30 | 2006-07-06 | Affymetrix, Inc. | Detection of polynucleotides on nucleic acid arrays using azido-modified triphosphate nucleotide analogs |
WO2006084202A2 (en) | 2005-02-03 | 2006-08-10 | The University Of North Carolina At Chapel Hill | Low surface energy polymeric material for use in liquid crystal displays |
EP1848460A4 (en) | 2005-02-11 | 2008-03-12 | Intezyne Technologies Inc | Synthesis of homopolymers and block copolymers |
CN101500420A (en) | 2005-02-25 | 2009-08-05 | 加州大学评议会 | New polymeric materials and methods |
AU2006231452B2 (en) | 2005-04-01 | 2011-05-26 | Intezyne Technologies, Inc. | Polymeric micelles for drug delivery |
US20080171067A1 (en) * | 2007-01-17 | 2008-07-17 | Immunomedics, Inc. | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites |
AU2006232310B9 (en) | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
US20100098640A1 (en) * | 2005-06-20 | 2010-04-22 | Cohen Seth M | Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation |
WO2007003054A1 (en) | 2005-07-06 | 2007-01-11 | Shoichet Molly S | Method of biomolecule immobilization on polymers using click-type chemistry |
US20070020620A1 (en) * | 2005-07-14 | 2007-01-25 | Finn M G | Compositions and methods for coupling a plurality of compounds to a scaffold |
JP2009506136A (en) * | 2005-07-18 | 2009-02-12 | ザ スクリプス リサーチ インスティテュート | Preparation of amphiphilic dendrimers |
WO2007011967A2 (en) | 2005-07-18 | 2007-01-25 | The Scripps Research Institute | Method of using click chemistry to functionalize dendrimers |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US20070060658A1 (en) * | 2005-08-31 | 2007-03-15 | Diaz David D | Stabilization of organogels and hydrogels by azide-alkyne [3+2] cycloaddition |
JP2009508991A (en) * | 2005-09-15 | 2009-03-05 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | Polymer composition and methods for making and using the same |
AU2006299641B2 (en) | 2005-09-30 | 2012-02-02 | Pacific Biosciences Of California, Inc. | Reactive surfaces, substrates and methods for producing and using same |
DK1943004T3 (en) | 2005-09-30 | 2015-08-31 | Scripps Research Inst | Ruthenium-catalyzed cycloaddition of alkynes and organic azides |
US7763423B2 (en) * | 2005-09-30 | 2010-07-27 | Pacific Biosciences Of California, Inc. | Substrates having low density reactive groups for monitoring enzyme activity |
CN101511389A (en) | 2005-10-04 | 2009-08-19 | 皇家飞利浦电子股份有限公司 | Targeted imaging and/or therapy using the [3+2] azide-alkyne cycloaddition |
AU2006304110B2 (en) * | 2005-10-12 | 2012-02-02 | The Scripps Research Institute | Selective posttranslational modification of phage-displayed polypeptides |
US20100247433A1 (en) | 2005-10-14 | 2010-09-30 | California Institute Of Technology | Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells |
CA2625403A1 (en) * | 2005-10-17 | 2007-04-26 | Institute For System Biology | Tissue-and serum-derived glycoproteins and methods of their use |
CN101534865A (en) * | 2005-10-19 | 2009-09-16 | Ibc药品公司 | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
WO2007056561A2 (en) | 2005-11-09 | 2007-05-18 | Liquidia Technologies, Inc. | Medical device, materials, and methods |
WO2008048288A2 (en) | 2005-11-09 | 2008-04-24 | Montana State University | Novel nanoparticles and use thereof |
US8944804B2 (en) | 2006-01-04 | 2015-02-03 | Liquidia Technologies, Inc. | Nanostructured surfaces for biomedical/biomaterial applications and processes thereof |
US8114636B2 (en) * | 2006-02-10 | 2012-02-14 | Life Technologies Corporation | Labeling and detection of nucleic acids |
WO2008029281A2 (en) | 2006-02-10 | 2008-03-13 | Invitrogen Corporation | Labeling and detection of post translationally modified proteins |
CA2642273C (en) | 2006-02-14 | 2016-09-20 | President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
US20070254006A1 (en) | 2006-02-15 | 2007-11-01 | Massachusetts Institute Of Technology | Medical Devices and Coatings with Non-Leaching Antimicrobial Peptides |
CA2642819C (en) * | 2006-03-10 | 2015-06-09 | Warwick Effect Polymers Ltd. | Sugar polymers |
US7909928B2 (en) | 2006-03-24 | 2011-03-22 | The Regents Of The University Of Michigan | Reactive coatings for regioselective surface modification |
US8206779B2 (en) * | 2006-03-24 | 2012-06-26 | Fujifilm Corporation | Method for producing laminate, polarizing plate, and image display device |
CA2861601A1 (en) * | 2006-04-27 | 2007-11-08 | Intezyne Technologies, Inc. | Poly (ethylene glycol) containing chemically disparate endgroups |
US20100048738A1 (en) * | 2006-05-15 | 2010-02-25 | Rhodia Operations | Hybrid compounds based on polyol(s) and at least one other molecular entity, polymeric or non-polymeric, in particular of the polyorganosiloxane type, process for the preparation thereof, and applications thereof |
US8501478B2 (en) * | 2006-06-15 | 2013-08-06 | University Of Cincinnati | Trehalose click polymers for delivery of biologically active molecules |
WO2008013618A1 (en) | 2006-06-21 | 2008-01-31 | Dendritic Nanotechnologies, Inc. | Process for preparing alkyne intermediates for dendritic polymers |
WO2008004988A1 (en) | 2006-07-06 | 2008-01-10 | Agency For Science, Technology And Research | Thermally responsive micelles |
US8066824B2 (en) * | 2006-07-07 | 2011-11-29 | Intezyne Technologies, Inc. | Covalent modification of metal surfaces |
US20090053139A1 (en) * | 2006-07-12 | 2009-02-26 | Regents Of The University Of Michigan | Dendrimer based compositions and methods of using the same |
US20100021391A1 (en) * | 2006-07-14 | 2010-01-28 | Montana State University | Novel nanoparticles for biofilm targeting |
US20080015138A1 (en) * | 2006-07-17 | 2008-01-17 | Affinergy, Inc. | Metal binding compounds, metal binding compositions, and their uses |
WO2008016371A1 (en) | 2006-08-01 | 2008-02-07 | The Trustees Of Columbia University In The City Ofnew York | Macromonomers for preparation of degradable polymers and model networks |
US20100047258A1 (en) * | 2006-08-02 | 2010-02-25 | Dong Wang | Drug Carriers, Their Synthesis, and Methods of Use Thereof |
US8124188B2 (en) * | 2006-08-18 | 2012-02-28 | Commonwealth Scientific And Industrial Research Organisation | Polymeric coatings and methods for forming them |
WO2008024435A2 (en) * | 2006-08-23 | 2008-02-28 | Vanderbilt University | Dendritic molecular intracellular transporters and methods of making and using same |
ITMI20061726A1 (en) | 2006-09-11 | 2008-03-12 | Fidia Farmaceutici | CROSSLINKATI DERIVATIVES BASED ON HYALURONIC ACID RETICULATED VIA CLICK CHEMISTRY |
US7985783B2 (en) * | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
WO2008048733A1 (en) * | 2006-10-17 | 2008-04-24 | Henkel Ag & Co. Kgaa | 1,3-dipolar cycloaddition of azides to alkynes |
FR2907456B1 (en) | 2006-10-20 | 2009-01-16 | Biocydex Soc Par Actions Simpl | PROCESS FOR THE PREPARATION OF OLIGOMERS OR POLYMERS OF CYCLODESTRINS |
US7861893B2 (en) * | 2006-11-10 | 2011-01-04 | Ethicon Endo-Surgery, Inc. | Adhesive dispenser for surgery |
CA2669970A1 (en) * | 2006-11-17 | 2008-05-22 | University Of Massachusetts Lowell | Functional hydrocarbon polymers and process for producing same |
WO2008075955A2 (en) | 2006-12-21 | 2008-06-26 | Stichting Voor De Technische Wetenschappen | Process for the preparation of 1,4,5-trisubstituted triazoles and 3,4,5-trisubstituted triazoles |
WO2008077406A2 (en) | 2006-12-22 | 2008-07-03 | Aalborg Universitet | Coupling of elements |
EP2115423B1 (en) * | 2007-01-05 | 2013-11-06 | Technische Universität München | Apparatus and method for the detection of forces in the sub-micronewton range |
AU2007345648A1 (en) * | 2007-01-26 | 2008-08-07 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
US20080199736A1 (en) * | 2007-02-16 | 2008-08-21 | Gadeken Larry L | Apparatus for generating electrical current from radioactive material and method of making same |
US7622532B2 (en) * | 2007-02-16 | 2009-11-24 | William Marsh Rice University | Synthesis of radioactive materials and compositions of same |
WO2008106657A2 (en) | 2007-03-01 | 2008-09-04 | Intezyne Technologies, Inc. | Encapsulated amyloid-beta peptides |
CN101679021B (en) | 2007-03-02 | 2014-04-30 | 伊利诺伊大学评议会 | Particulate drug delivery |
WO2008108736A1 (en) | 2007-03-06 | 2008-09-12 | Agency For Science, Technology And Research | Particles for delivery of bioactive factors |
WO2008115694A2 (en) | 2007-03-16 | 2008-09-25 | Medtronic, Inc. | Polymerization of multifunctional azides, and polymers therefrom |
US7910319B2 (en) | 2007-03-23 | 2011-03-22 | Academia Sinica | Glycoproteomic probes for fluorescent imaging fucosylated glycans in vivo |
US20080241892A1 (en) | 2007-03-29 | 2008-10-02 | Pacific Biosciences Of California, Inc. | Modified surfaces for immobilization of active molecules |
US8277711B2 (en) | 2007-03-29 | 2012-10-02 | E I Du Pont De Nemours And Company | Production of nanofibers by melt spinning |
GB0706243D0 (en) | 2007-03-30 | 2007-05-09 | Univ Southampton | Modified nucleic acids |
EP1975230A1 (en) | 2007-03-30 | 2008-10-01 | Capsulution Nanoscience AG | Method for forming glucose sensing micro-particles, use of micro-particles, and kit |
US7798385B2 (en) | 2007-05-16 | 2010-09-21 | The Invention Science Fund I, Llc | Surgical stapling instrument with chemical sealant |
US7909795B2 (en) * | 2007-07-05 | 2011-03-22 | Baxter International Inc. | Dialysis system having disposable cassette and interface therefore |
US20090018646A1 (en) * | 2007-07-10 | 2009-01-15 | Zhao Jonathon Z | Coating Employing an Anti-Thrombotic Conjugate |
EP2090592A1 (en) | 2007-07-31 | 2009-08-19 | OctoPlus Sciences B.V. | Biodegradable hydrogels based on click chemistry |
WO2009020550A2 (en) * | 2007-08-03 | 2009-02-12 | University Of Massachusetts Medical School | Composites for biomedical applications |
US8927682B2 (en) * | 2007-08-24 | 2015-01-06 | Board Of Trustees Of Michigan State University | Functionalization of polyglycolides by “click” chemistry |
PL2644594T3 (en) * | 2007-09-28 | 2018-01-31 | Pfizer | Cancer Cell Targeting Using Nanoparticles |
EP2219587A4 (en) | 2007-11-14 | 2012-11-21 | Univ California | Sterol-modified amphiphilic lipids |
US8092855B2 (en) * | 2007-11-28 | 2012-01-10 | California Institute Of Technology | Click chemistry surface functionalization for resonant micro-cavity sensors |
US8709393B2 (en) | 2008-01-30 | 2014-04-29 | Wound Engineering Llc | Methods and compositions for wound healing |
US8034396B2 (en) * | 2008-04-01 | 2011-10-11 | Tyco Healthcare Group Lp | Bioadhesive composition formed using click chemistry |
US8440176B2 (en) * | 2008-04-25 | 2013-05-14 | Interface Biologics, Inc. | Covalently grafted pharmaceutically active polymers |
WO2009136853A1 (en) | 2008-05-07 | 2009-11-12 | Polymer Factory Sweden Ab | Dendrimers with interior and exterior functionalities comprising of azide or alkyne groups for post- functionalization by huisgen click cycloaddition |
US9339558B2 (en) | 2008-05-13 | 2016-05-17 | University Of Washington | Micellic assemblies |
-
2010
- 2010-02-19 US US12/708,828 patent/US8663689B2/en active Active
- 2010-02-22 EP EP13156082.3A patent/EP2606915B1/en not_active Not-in-force
- 2010-02-22 AU AU2010215195A patent/AU2010215195B2/en not_active Ceased
- 2010-02-22 EP EP10713708.5A patent/EP2398512B1/en not_active Not-in-force
- 2010-02-22 WO PCT/IB2010/000589 patent/WO2010095048A2/en active Application Filing
- 2010-02-22 CA CA2753177A patent/CA2753177A1/en not_active Abandoned
-
2014
- 2014-01-14 US US14/154,338 patent/US20140128497A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050089578A1 (en) * | 2001-02-05 | 2005-04-28 | Werkmeister Jerome A. | Methods and devices for tissue repair |
US20090226499A1 (en) * | 2008-03-03 | 2009-09-10 | New York University | Biocompatible materials containing stable complexes of tsg-6 and hyaluronan and method of using same |
Non-Patent Citations (4)
Title |
---|
CRESCENZI et al (Novel hydrogels via click chemistry: synthesis and potential biomedical applications. Biomacromolecules. 2007 Jun;8(6):1844-50. Epub 2007 May 25) * |
DIAZ (Click Chemistry in Materials Synthesis. 1. Adhesive Polymers from Copper-Catalyzed Azide-Alkyne Cycloaddition. Journal of Polymer Science: Part A: Polymer Chemistry, Vol. 42, 4392-4403 (2004). * |
SLETTEN et al (A Hydrophilic Azacyclooctyne for Cu-Free Click Chemistry. Org. Lett., 2008, 10 (14), pp 3097â3099) * |
SPEERS et al (Activity-Based Protein Profiling in Vivo Using a Copper(I)-Catalyzed Azide-Alkyne [3 + 2] Cycloaddition. J. Am. Chem. Soc., 2003, 125 (16), pp 4686â4687). * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10155063B2 (en) | 2015-11-12 | 2018-12-18 | University Of Virginia Patent Foundation | Methods for vas-occlusive contraception and reversal thereof |
US11278641B2 (en) | 2015-11-12 | 2022-03-22 | University Of Virginia Patent Foundation | Occlusive implant compositions |
US11904068B2 (en) | 2015-11-12 | 2024-02-20 | University Of Virginia Patent Foundation | Occlusive implant compositions |
US10751124B2 (en) | 2017-01-05 | 2020-08-25 | Contraline, Inc. | Methods for implanting and reversing stimuli-responsive implants |
US11253391B2 (en) | 2018-11-13 | 2022-02-22 | Contraline, Inc. | Systems and methods for delivering biomaterials |
US11318040B2 (en) | 2018-11-13 | 2022-05-03 | Contraline, Inc. | Systems and methods for delivering biomaterials |
US11510807B2 (en) | 2018-11-13 | 2022-11-29 | Contraline, Inc. | Systems and methods for delivering biomaterials |
US11951032B2 (en) | 2018-11-13 | 2024-04-09 | Contraline, Inc. | Systems and methods for delivering biomaterials |
US11957616B2 (en) | 2018-11-13 | 2024-04-16 | Contraline, Inc. | Systems and methods for delivering biomaterials |
Also Published As
Publication number | Publication date |
---|---|
US20100215748A1 (en) | 2010-08-26 |
WO2010095048A3 (en) | 2010-12-16 |
EP2606915B1 (en) | 2014-11-05 |
EP2398512B1 (en) | 2013-11-20 |
US8663689B2 (en) | 2014-03-04 |
EP2398512A2 (en) | 2011-12-28 |
EP2606915A2 (en) | 2013-06-26 |
AU2010215195A1 (en) | 2011-10-13 |
WO2010095048A2 (en) | 2010-08-26 |
EP2606915A3 (en) | 2013-07-31 |
AU2010215195B2 (en) | 2014-10-30 |
CA2753177A1 (en) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8663689B2 (en) | Functionalized adhesive medical gel | |
US9180221B2 (en) | Functionalized adhesive for medical devices | |
US9510810B2 (en) | Medical devices incorporating functional adhesives | |
US8512728B2 (en) | Method of forming a medical device on biological tissue | |
US9554782B2 (en) | Medical devices incorporating functional adhesives | |
US9987297B2 (en) | Polymeric fibers having tissue reactive members |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SOFRADIM PRODUCTION, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LADET, SEBASTIEN;GRAVAGNA, PHILIPPE;SIGNING DATES FROM 20100329 TO 20100330;REEL/FRAME:032218/0659 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |